

Db 39 SRKVTYTLTKNTYRLKLSLRWISDHEYLKQENNLVFNAEYGNSSVFLNSTDFEF 98
Qy 73 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSASDIYDLNKRQLITEERIPNNTQWTVWS 132
Db 99 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSASDIYDLNKRQLITEERIPNNTQWTVWS 158
Qy 133 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSALWSP 192
Db 159 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSALWSP 218
Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPTKTRVPYPKAGAVNPTKFFVNTDLSLSS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPTKTRVPYPKAGAVNPTKFFVNTDLSLSS 278
Qy 253 VTNATSIQITAPASMLIGDHYLCVDTWATQBRISLQWLRRIONTSVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHYLCVDTWATQBRISLQWLRRIONTSVMDICDYDESSGRWN 338
Qy 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 398
Qy 373 KGTWEVIGIEALTSDLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPERCOYYS 432
Db 399 KGTWEVIGIEALTSDLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPERCOYYS 458
Qy 433 VFSKKAQYQLRCSGPGPLPYTLHSSVNDKGLRVLEDSALDKMLQNVQMPKCLDFII 492
Db 459 VFSKKAQYQLRCSGPGPLPYTLHSSVNDKGLRVLEDSALDKMLQNVQMPKCLDFII 518
Qy 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 578
Qy 553 DGRSGYQGDKIMHAINRRLGTPEVEDQIEAARQFSKMGFVNDKRIALWGSYGGYVTSM 612
Db 579 DGRSGYQGDKIMHAINRRLGTPEVEDQIEAARQFSKMGFVNDKRIALWGSYGGYVTSM 638
Qy 613 VLGSQGVFKGCIAPVPSRWEYVDSVYTERYMGLPTEPDMLDHYRNSTVMSRAENFKQV 672
Db 639 VLGSQGVFKGCIAPVPSRWEYVDSVYTERYMGLPTEPDMLDHYRNSTVMSRAENFKQV 698
Qy 673 EYLLIHGTADDNVHFQOASQISKALVDGVDFQAWWYTDDEHGIASSTAHOHIYTHMSHF 732
Db 699 EYLLIHGTADDNVHFQOASQISKALVDGVDFQAWWYTDDEHGIASSTAHOHIYTHMSHF 758
Qy 733 IKQCFSLP 740
Db 759 IKQCFSLP 766

RESULT 32
AAR54611
ID AAR54611 standard; protein; 766 AA.
XX
AC AAR54611;

XX
DT 25-MAR-2003 (revised)
XX 09-DEC-1994 (first entry)

DE Native CD26.
XX Human; T cell activation antigen; CD26; analogues; deletion; soluble;
KW signal peptidase; immune-stimulating; response-stimulating; AIDS;
KW immunosuppression; AIDS-related complex.
XX Homo sapiens.
XX WO9409132-A1.
PN
XX
PD 28-APR-1994.
XX

PF 19-AUG-1993; 93WO-US007923.
PR 21-AUG-1992; 92US-00934162.
PA (DAND) DANA FARBER CANCER INST INC.
XX
PI Morimoto C, Schlossman S, Tanaka T;
XX
DR WPI; 1994-151317/18.
DR N-PSDB; AAQ63261.

Polypeptide fragments and analogues of CD26 and encoding nucleic acid -
useful for stimulating immune response, e.g. for treatment of AIDS to
counteract immunosuppressive drug, and as vaccine adjuvant.

Disclosure; Page 46-49; 85pp; English.

This sequence represents the human T cell activation antigen CD26. The
invention is concerned with polypeptide fragments and analogues of CD26
which have internal deletions (see also AAR54612-14). The analogues pref.
lack residues 3-9 or 24-34. These analogues are soluble under
physiological conditions and lack enough amino acid residues to render
them susceptible to cleavage by signal peptidase. The peptide fragments
and analogues are useful as immune or response- stimulating therapeutics,
eg. they may be used for treatment of disease conditions characterised by
immunosuppression, eg. AIDS or AIDS-related complex, other virally or
environmentally-induced conditions, and certain congenital immune
deficiencies. The peptides can be employed to increase immune function
which has been impaired by use of immunosuppressive drugs, such as certain
chemotherapeutic drugs. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 766 AA;

Query Match 97.7%; Score 3928; DB 2; Length 766;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 SRKTYTLTKNTYRLKLSLRWISDHEYLKQENNLVFNAEYGNSSVFLNSTDFEF 72
Db 39 SRKTYTLTKNTYRLKLSLRWISDHEYLKQENNLVFNAEYGNSSVFLNSTDFEF 98
Qy 73 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSASDIYDLNKRQLITEERIPNNTQWTVWS 132
Db 99 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSASDIYDLNKRQLITEERIPNNTQWTVWS 158
Qy 133 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSALWSP 192
Db 159 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSALWSP 218
Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPTKTRVPYPKAGAVNPTKFFVNTDLSLSS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPTKTRVPYPKAGAVNPTKFFVNTDLSLSS 278
Qy 253 VTNATSIQITAPASMLIGDHYLCVDTWATQBRISLQWLRRIONTSVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHYLCVDTWATQBRISLQWLRRIONTSVMDICDYDESSGRWN 338
Qy 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 398
Qy 373 KGTWEVIGIEALTSDLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPERCOYYS 432
Db 399 KGTWEVIGIEALTSDLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPERCOYYS 458
Qy 433 VFSKKAQYQLRCSGPGPLPYTLHSSVNDKGLRVLEDSALDKMLQNVQMPKCLDFII 492
Db 459 VFSKKAQYQLRCSGPGPLPYTLHSSVNDKGLRVLEDSALDKMLQNVQMPKCLDFII 518
Qy 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 578

QY 673 EYLLIHGTADDNVHFQOQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIIYTHMSHF 732
 DB 699 EYLLIHGTADDNVHFQOQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIIYTHMSHF 758

QY 733 IKQCFSLP 740
 DB 759 IKQCFSLP 766

RESULT 29

ID ABP55629 standard; protein; 766 AA.

AC ABP55629;

DT 20-FEB-2003 (first entry)

DE Human dpp4 protein sequence.

KW DPP10; dipeptidyl peptidase; prolololigopeptidase; enzyme; asthma;
 KW antiinflammatory; antiasthmatic; antipsoriatic; antiarthritis;
 KW antirheumatic; vaccine; gene therapy; inflammatory disease;
 KW inflammatory bowel disease; atopy; rheumatoid arthritis; psoriasis;
 KW chromosome 2q14.

XX Homo sapiens.

XX WO200286113-A2.

XX 31-OCT-2002.

XX 24-APR-2002; 2002WO-GB001887.

XX 24-APR-2001; 2001GB-00010044.

XX 24-APR-2001; 2001GB-00010046.

XX 12-OCT-2001; 2001GB-00024575.

XX 12-OCT-2001; 2001GB-00024594.

XX (ISIS-) ISIS INNOVATIONS LTD.

XX Cookson WOCM, Moffat MF, Allen M, Lench N;

XX WPI; 2003-093132/08.

XX New nucleic acid sequence comprising DPP10 mRNA, useful for the
 PT manufacture of a medicament for regulating DPP10 protein expression or
 PT for preventing or treating inflammatory disease e.g., inflammatory bowel
 PT disease.

XX Example 2; Fig 23; 321pp; English.

XX The present invention describes a new isolated nucleic acid sequence (I)
 CC comprising a DPP10 mRNA sequence. DPP10 is a dipeptidyl peptidase (also
 CC known as prolololigopeptidase). (I) has antiinflammatory, antiasthmatic,
 CC antipsoriatic, antiarthritis and antirheumatic activities, and can be
 CC used in vaccines and gene therapy. A composition comprising (I) can be
 CC used for the manufacture of a medicament for regulating DPP10 expression
 CC or for preventing or treating inflammatory disease e.g., inflammatory
 CC bowel disease, asthma, atopy, rheumatoid arthritis or psoriasis. (I) can
 CC also be used in an assay for detecting or measuring DPP10 in a sample. A
 CC host cell comprising (I) can be used for producing recombinant DPP10 gene
 CC products, or in drug screening systems to identify agents for diagnosis
 CC or treatment of individuals having or susceptible to inflammatory
 CC disease. Human DPP10 is located on chromosome 2, more specifically
 CC chromosome 2q14. ABQ84254 to ABQ84612 and ABP55569 to ABP55629 represent
 CC sequences used in the exemplification of the present invention

XX Sequence 766 AA;

Query Match 97.7%; Score 3929; DB 6; Length 766;
 Best Local Similarity 99.7%; Pred. No. 0;
 Matches 726; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 13 SRKTYTLTDYLNKTYRLKLSLRWISDHEYLKQENNILVFNABYGNSSVFLENSTDFEF 72
 DB 39 SRKTYTLTDYLNKTYRLKLSLRWISDHEYLKQENNILVFNABYGNSSVFLENSTDFEF 98
 QY 73 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSYDIYDLNKRQLITBERIPNNTQWVTWS 132
 DB 99 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSYDIYDLNKRQLITBERIPNNTQWVTWS 158
 QY 133 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTYBEVFPAYSALWWSF 192
 DB 159 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTYBEVFPAYSALWWSF 218
 QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRVPYKAGAVNPTVKFPVNTDSLS 252
 DB 219 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRVPYKAGAVNPTVKFPVNTDSLS 278
 QY 253 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWN 312
 DB 279 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWN 338
 QY 313 CLVARQHIEMSTTGWVGRFRPSPHFTLDGNSFYKIIISNBEGRHICYFQIDKXCTFIT 372
 DB 339 CLVARQHIEMSTTGWVGRFRPSPHFTLDGNSFYKIIISNBEGRHICYFQIDKXCTFIT 398
 QY 373 KGTWEVIGIEALTSDYLYIISNEYKGMPPGGRNLYKIQLSDYTKVTCLSCELNPERCOYYS 432
 DB 399 KGTWEVIGIEALTSDYLYIISNEYKGMPPGGRNLYKIQLSDYTKVTCLSCELNPERCOYYS 458
 QY 433 VSFSEAKAYYQLRCSGFLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKLDFII 492
 DB 459 VSFSEAKAYYQLRCSGFLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKLDFII 518
 QY 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 552
 DB 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 578
 QY 553 DGRSGYQGDKIMHAINRRILGTREVDQIEAARQFSKMGFVDNKRIAIWGWSYGYVTSM 612
 DB 579 DGRSGYQGDKIMHAINRRILGTREVDQIEAARQFSKMGFVDNKRIAIWGWSYGYVTSM 638
 QY 613 VLGSGGVFKCGIAPVSRWEYDYSVYTERYMGLEPTPEDNLDHYRNSTVMSRAENFKQV 672
 DB 639 VLGSGGVFKCGIAPVSRWEYDYSVYTERYMGLEPTPEDNLDHYRNSTVMSRAENFKQV 698
 QY 673 EYLLIHGTADDNVHFQOQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIIYTHMSHF 732
 DB 699 EYLLIHGTADDNVHFQOQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIIYTHMSHF 758
 QY 733 IKQCFSLP 740
 DB 759 IKQCFSLP 766
 RESULT 30
 ADQ80365
 ID ADQ80365 standard; protein; 766 AA.
 AC ADQ80365;
 XX 21-OCT-2004 (first entry)
 DT Dipeptidylpeptidase IV protein.
 DE
 XX cytotatic; epidermal growth factor receptor modulator; identification;
 KW therapeutic response; cancer; EGFR; biomarker.
 XX
 OS Homo sapiens.
 XX
 XX WO2004063709-A2.
 XX
 XX 29-JUL-2004.
 XX

QY 73 GHSINDYSISDPGQFILLEYNVYKQWRHSYASVDIYDLNKRQLITEERIINNNTQWTVWS 132
DB 99 GHSINDYSISDPGQFILLEYNVYKQWRHSYASVDIYDLNKRQLITEERIINNNTQWTVWS 158
QY 133 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWVYEEVFSAYSALWMSF 192
DB 159 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWVYEEVFSAYSALWMSF 218
QY 193 NGTFLAYAQFNDTEVPLIEYFYSDESLOYPKTVRVPYKAGAVNPTVKFFVNVNTDLSLSS 252
DB 219 NGTFLAYAQFNDTEVPLIEYFYSDESLOYPKTVRVPYKAGAVNPTVKFFVNVNTDLSLSS 278
QY 253 VTNATSIQITAPASMLIGDHLYCDVWATQBRISLQWRRIQNTSVMDICDYDSSGRWN 312
DB 279 VTNATSIQITAPASMLIGDHLYCDVWATQBRISLQWRRIQNTSVMDICDYDSSGRWN 338
QY 313 CLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKLIISNEEGYRHICYFQIDKDCFTIT 372
DB 339 CLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKLIISNEEGYRHICYFQIDKDCFTIT 398
QY 373 KGTWEVIGIEALTSDLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPRCQYYS 432
DB 399 KGTWEVIGIEALTSDLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPRCQYYS 458
QY 433 VSFSEAKYQYLRCSGGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 492
DB 459 VSFSEAKYQYLRCSGGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 518
QY 493 LNETKFWYQMLPPHFDKSKYKYPDLLDYVYAGPCQKADTVFRLNWTATYLASTENIIVASF 552
DB 519 LNETKFWYQMLPPHFDKSKYKYPDLLDYVYAGPCQKADTVFRLNWTATYLASTENIIVASF 578
QY 553 DGRSGYQGDKIMHAINRLGTPEVEDQIEAARQFSKMGFVNDKRIALWGSYGYVTSM 612
DB 579 DGRSGYQGDKIMHAINRLGTPEVEDQIEAARQFSKMGFVNDKRIALWGSYGYVTSM 638
QY 613 VLGSYGKVFKGIAVAPVSRWEYDVSVTERYMGILPTPEDNLDHYRNSVMSRAENPKQV 672
DB 639 VLGSYGKVFKGIAVAPVSRWEYDVSVTERYMGILPTPEDNLDHYRNSVMSRAENPKQV 698
QY 673 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIYTHMSHF 732
DB 699 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIYTHMSHF 758
QY 733 IKQCFSLP 740
DB 759 IKQCFSLP 766
RESULT 27
ADN39604
ID ADN39604 standard; protein; 766 AA.
XX AC ADN39604;
XX DT 17-JUN-2004 (first entry)
XX DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:A204.
XX KW Human; differential expression; cancer; angiogenic disorder;
KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;
KW inflammatory disease; autoimmune disease;
KW retinal neovascularisation syndrome; scarring; uterine fibroid;
KW detection; diagnosis; prognosis; drug screening; drug targeting;
KW wound healing; contraception; cytostatic; cardiatic; immunomodulatory;
KW vulnerable; gene therapy; vaccine.
XX OS Homo sapiens.
XX PN WO2003042661-A2.
XX PD 22-MAY-2003.

XX PF 13-NOV-2002; 2002WO-US036810.
XX PR 13-NOV-2001; 2001US-0350666P.
PR 21-NOV-2001; 2001US-0332464P.
PR 29-NOV-2001; 2001US-0334393P.
PR 03-DEC-2001; 2001US-0335394P.
PR 14-DEC-2001; 2001US-0340376P.
PR 08-JAN-2002; 2002US-0347211P.
PR 10-JAN-2002; 2002US-0347349P.
PR 08-FEB-2002; 2002US-035250P.
PR 13-FEB-2002; 2002US-0356714P.
PR 20-FEB-2002; 2002US-0359077P.
PR 29-MAR-2002; 2002US-036809P.
PR 04-APR-2002; 2002US-0370110P.
PR 12-APR-2002; 2002US-0372246P.
PR 05-JUN-2002; 2002US-0386614P.
PR 16-JUL-2002; 2002US-0396839P.
PR 22-JUL-2002; 2002US-0397775P.
PR 22-JUL-2002; 2002US-0397845P.
PR 09-SEP-2002; 2002US-0409450P.
XX (EOSB-) EOS BIOTECHNOLOGY INC.
PA Afar D, Aziz N, Gineburg WM, Gish KC, Glynn R, Hevezi PA;
PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;
XX WPI; 2003-468649/44.
DR N-PSDB; ADN39603.
XX Determining the presence or absence of a pathological cell in a patient,
PT useful for diagnosing, prognosing or treating cancer, comprises detecting
PT a nucleic acid in a biological sample.
XX Claim 12; SEQ ID NO A204; 1385bp; English.
XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)
CC whose expression is upregulated or downregulated in specific cancers or
CC other diseases such as angiogenic or fibrotic disorders, and to methods
CC of determining the presence or absence of a pathological cell in a
CC patient by detecting a nucleic acid at least 80% identical to those of
CC the invention or by detecting a polypeptide of the invention. The
CC invention also relates to expression vectors and host cells comprising a
CC nucleic acid of the invention; antibodies which specifically bind a
CC polypeptide of the invention; use of such antibodies for drug targeting;
CC and methods of screening for modulators of activity or expression of the
CC polypeptides and nucleic acids. The nucleic acids, polypeptides,
CC antibodies and methods are useful for diagnosing, prognosing and treating
CC cancer and other conditions such as psoriasis, ischaemia, heart disease,
CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal
CC neovascularisation syndromes, scarring and uterine fibroids. They may
CC also be useful in wound healing and in contraception. The present
CC sequence represents a polypeptide of the invention.
XX SQ Sequence 766 AA;
Query Match 97.8%; Score 3933; DB 7; Length 766;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 13 SRKTYTLTDYKNTYRLKLYSLRWISDHEVLYKQENNLVFNAYGNSSVFLNSTDFEF 72
DB 39 SRKTYTLTDYKNTYRLKLYSLRWISDHEVLYKQENNLVFNAYGNSSVFLNSTDFEF 98
QY 73 GHSINDYSISDPGQFILLEYNVYKQWRHSYASVDIYDLNKRQLITEERIINNNTQWTVWS 132
DB 99 GHSINDYSISDPGQFILLEYNVYKQWRHSYASVDIYDLNKRQLITEERIINNNTQWTVWS 158
QY 133 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWVYEEVFSAYSALWMSF 192
DB 159 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWVYEEVFSAYSALWMSF 218
QY 193 NGTFLAYAQFNDTEVPLIEYFYSDESLOYPKTVRVPYKAGAVNPTVKFFVNVNTDLSLSS 252

CC antidiabetic, hypotensive, nephrotropic, antiarthritic and
CC antiinflammatory activities, and can be used in gene therapy. (M1) is
CC useful in targeting pharmaceuticals or other therapeutics to specific
CC tissues using tissue-specific endothelial membrane proteins. A
CC therapeutic complex may be used to treat or diagnose any disease for
CC which a tissue- or organ-specific treatment would be efficacious, such as
CC in cases of infections (e.g. bacterial, viral, fungal and parasitic),
CC epilepsy, schizophrenia, cancer, Parkinson's disease, Alzheimer's
CC disease, asthma, diabetes, hypertension, polycystic kidney disease,
CC arthritis, and inflammatory bowel disease. The present sequence
CC represents a human liver dipeptidyl peptidase IV (DPP4), which is used in
CC an example from the present invention
XX
SQ Sequence 766 AA;

Query Match 97.8%; Score 3933; DB 6; Length 766;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 13 SRKTYTLTDYLNKNTYRLKLYSLRWISDHEYLKQENNLVFNAYGNSVFLNSTFDEF 72
DB 39 SRKTYTLTDYLNKNTYRLKLYSLRWISDHEYLKQENNLVFNAYGNSVFLNSTFDEF 98
QY 73 GHSINDYSISPGQIFILEYNYVVKQWRHSYTASYDIYDLNKLQITEERIPNNTQVWTWS 132
DB 99 GHSINDYSISPGQIFILEYNYVVKQWRHSYTASYDIYDLNKLQITEERIPNNTQVWTWS 158
QY 133 PVGHKLAYVWNNDIYVKLEPNLPSYRIITWTGKEDIYNGITDMWYEEVFSAYSALWSP 192
DB 159 PVGHKLAYVWNNDIYVKLEPNLPSYRIITWTGKEDIYNGITDMWYEEVFSAYSALWSP 218
QY 193 NGTFLAYAQFNDTEVPLEIYSFYSDESQYPTKTRVPYKAGAVNPTVKFFVNTDSLSS 252
DB 219 NGTFLAYAQFNDTEVPLEIYSFYSDESQYPTKTRVPYKAGAVNPTVKFFVNTDSLSS 278
QY 253 VTNATSIQTAPASMLIGHYICDVTWATQERISLOWLRRIQNSYMDICDYDESSGRWN 312
DB 279 VTNATSIQTAPASMLIGHYICDVTWATQERISLOWLRRIQNSYMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTGWRFRPPEPFTLDGNSFYKLIISNEEGYRHICYFQIDKDCCTFIT 372
DB 339 CLVARQHIEMSTGWRFRPPEPFTLDGNSFYKLIISNEEGYRHICYFQIDKDCCTFIT 398
QY 373 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
DB 399 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458
QY 433 VSFSEAKYQYLRCSGPGPLTYLTHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFTI 492
DB 459 VSFSEAKYQYLRCSGPGPLTYLTHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFTI 518
QY 493 LNETKFWYQMLPPHFDKSKYPLLDVYAGPCOKADTVPRLNWATYLASTENIIVASF 552
DB 519 LNETKFWYQMLPPHFDKSKYPLLDVYAGPCOKADTVPRLNWATYLASTENIIVASF 578
QY 553 DGRGSGYQGDKIMHAINRLRGTFEVEDQIEAARQFSKMGFVNDKRIAINGWYGGYVISM 612
DB 579 DGRGSGYQGDKIMHAINRLRGTFEVEDQIEAARQFSKMGFVNDKRIAINGWYGGYVISM 638
QY 613 VLGSYGKVFCKGIAVAPSRWBYSDYVYTERYVGLPTPEDNLDHYRNSVTMSRAENFKQV 672
DB 639 VLGSYGKVFCKGIAVAPSRWBYSDYVYTERYVGLPTPEDNLDHYRNSVTMSRAENFKQV 698
QY 673 EYLLHGTADDNVHFOQSAQISKALVDGVDFQAMWYTDDEHGIASSTAHOHYTHMSHF 732
DB 699 EYLLHGTADDNVHFOQSAQISKALVDGVDFQAMWYTDDEHGIASSTAHOHYTHMSHF 758
QY 733 IKQCFSLP 740
DB 759 IKQCFSLP 766

ADD14045

ID ADD14045 standard; protein; 766 AA.

XX AC ADD14045;

XX DT 01-JAN-2004 (first entry)

XX DE Human src biomarker polypeptide SEQ ID NO:234.

XX KW predictor set; protein tyrosine kinase activity modulator;

XX KW protein tyrosine kinase pathway; protein tyrosine kinase; cytostatic;

XX KW gene therapy; drug sensitivity; genetic profile; cancer; human.

XX OS Homo sapiens.

XX PN WO2003062395-A2.

XX PD 31-JUL-2003.

XX PF 17-JAN-2003; 2003WO-US001981.

XX PR 18-JAN-2002; 2002US-0350061P.

XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.

XX PI Huang F, Fairchild CR, Lee FY, Shaw P;

XX DR WPI; 2003-636735/60.

XX DR N-PSDB; ADD14640.

PT New polynucleotides and polypeptides for predicting the activity of
PT compounds that interact with protein tyrosine kinases and/or protein
PT tyrosine kinase pathways.

PS Claim 10; SEQ ID NO 234; 139pp; English.

XX The present invention describes a predictor set comprising a plurality of
CC polynucleotides or polypeptides whose expression pattern is predictive of
CC the response of cells to treatment with a compound that modulates protein
CC tyrosine kinase activity or members of the protein tyrosine kinase
CC pathway. Also described: (1) predicting whether a compound is capable of
CC modulating the activity of cells, comprising obtaining a sample of cells,
CC determining whether the cells express a plurality of markers, and
CC correlating the expression of the markers to the compound's ability to
CC modulate the activity of the cells; (2) a plurality of cell lines for
CC identifying polynucleotides and polypeptides whose expression levels
CC correlate with compound sensitivity or resistance of cells associated
CC with a disease state; and (3) identifying polynucleotides and
CC polypeptides that predict compound sensitivity or resistance of cells
CC associated with a disease state, comprising subjecting the plurality of
CC cell lines to one or more compounds, analysing the expression pattern of
CC a microarray of polynucleotides or polypeptides, and selecting
CC polynucleotides or polypeptides that predict the sensitivity or
CC resistance of cells associated with a disease state by using the
CC expression pattern of the microarray. The polynucleotides and
CC polypeptides have cytostatic activities, and can be used in gene therapy.
CC The polynucleotides and polypeptides are useful in predicting the
CC activity of compounds that interact with protein tyrosine kinases and/or
CC protein tyrosine kinase pathways. These may be used in determining drug
CC sensitivity in patients to allow the development of individualized
CC genetic profiles which aid in treating diseases and disorders (e.g.
CC cancer) based on patient response at a molecular level. The present
CC sequence is used in the exemplification of the present invention.

SQ Sequence 766 AA;

? Query Match 97.8%; Score 3933; DB 7; Length 766;

Best Local Similarity 99.9%; Pred. No. 0;

Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 13 SRKTYTLTDYLNKNTYRLKLYSLRWISDHEYLKQENNLVFNAYGNSVFLNSTFDEF 72

DB 39 SRKTYTLTDYLNKNTYRLKLYSLRWISDHEYLKQENNLVFNAYGNSVFLNSTFDEF 98

Db 669 EYLLIHGTADDNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIIASSTAHOHYTHMSHF 728

Qy 733 IKQCFSLP 740

Db 729 IKQCFSLP 736

RESULT 23

ABG61910

ID ABG61910 standard; protein; 766 AA.

XX

AC ABG61910;

DT 15-AUG-2002 (first entry)

XX

DE Prostate cancer-associated protein #111.

XX

KW Prostate cancer; prostate tumour tissue; human; mammal; cytostatic.

XX

OS Mammalia.

XX

PN WO200230268-A2.

XX

PD 18-APR-2002.

XX

PF 12-OCT-2001; 2001WO-US032045.

XX

PR 13-OCT-2000; 2000US-00687576.

XX

PR 08-DEC-2000; 2000US-00733288.

XX

PR 08-DEC-2000; 2000US-00733742.

XX

PR 24-JAN-2001; 2001US-0263957P.

XX

PR 16-MAR-2001; 2001US-0276791P.

XX

PR 16-MAR-2001; 2001US-0276888P.

XX

PR 06-APR-2001; 2001US-0281922P.

XX

PR 24-APR-2001; 2001US-0286214P.

XX

PR 30-APR-2001; 2001US-0084704P.

XX

PR 04-MAY-2001; 2001US-0288589P.

XX

PA (EOSB-) EOS BIOTECHNOLOGY INC.

XX

PI Gish KC, Mack DH, Wilson KE, Afar D, Hevezi P;

XX

WPI; 2002-471335/50.

XX

DR N-PSDB; ABK92227.

XX

PT Detecting a prostate cancer-associated transcript in a cell in a patient,

XX

PT useful for diagnosing prostate cancer (PC) or screening modulators of PC,

XX

PT by determining if prostate cancer-associated genes are expressed in a

XX

PS Claim 27; Page 393; 436pp; English.

XX

CC The present invention relates to methods of detecting a prostate cancer-

XX

CC associated transcript in a cell from a patient. The method comprises

XX

CC contacting a biological sample from the patient with prostate cancer-

XX

CC associated polynucleotides (designated PC genes) that selectively

XX

CC hybridise to a sequence that is at least 80% identical to them. The

XX

CC prostate cancer-associated polynucleotide sequences are differentially

XX

CC expressed in prostate tumour tissue or in prostate cancer and are derived

CC from the tissues of various organisms such as humans or other mammals

CC (e.g. mice, sheep and dogs). The methods of the invention are useful for

CC diagnosing and treating prostate cancer in mammals. The prostate cancer-

CC associated genes are useful for diagnosing or treating prostate cancer,

CC as well as for identifying modulators of prostate cancer or agents that

CC inhibit prostate cancer. The nucleic acid sequences are particularly

CC useful in gene therapy, as a vaccine or in antisense applications.

CC ABG61800-ABG61944 represent prostate cancer-associated proteins

XX

SQ Sequence 766 AA;

Query Match 97.8%; Score 3933; DB 5; Length 766;

Best Local Similarity 99.9%; Pred. No. 0;

Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 SRKTYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFNABYGNSSVFLNSTFDEF 72

Db 39 SRKTYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFNABYGNSSVFLNSTFDEF 98

Qy 73 GHSINDYSISPDGQFILLLEYNVQWRHSYTSYDIYDLNKRQLITEIRIPNNTQWVTWS 132

Db 99 GHSINDYSISPDGQFILLLEYNVQWRHSYTSYDIYDLNKRQLITEIRIPNNTQWVTWS 158

Qy 133 PVGHKLAVVWNDIYVKIEPNLPSVRIITWTKGEDIYNGITDWWYEEVFSAYSALWSP 192

Db 159 PVGHKLAVVWNDIYVKIEPNLPSVRIITWTKGEDIYNGITDWWYEEVFSAYSALWSP 218

Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDSLQYPKTVRVPYPKAGAVNPTVKFFVNTDSLSS 252

Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDSLQYPKTVRVPYPKAGAVNPTVKFFVNTDSLSS 278

Qy 253 VTNATSIQITAPASMLIGDHYLCVDTWATQRIISLOWLRRIONYSVMDCIDYDESSGRWN 312

Db 279 VTNATSIQITAPASMLIGDHYLCVDTWATQRIISLOWLRRIONYSVMDCIDYDESSGRWN 338

Qy 313 CLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIIISNEGYRHCYFQIDKKDCTFIT 372

Db 339 CLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIIISNEGYRHCYFQIDKKDCTFIT 398

Qy 373 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYVS 432

Db 399 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLDYTKVTCLSCELNPERCQYVS 458

Qy 433 VFSKAEKYYQIRCSGPGPLPYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDPII 492

Db 459 VFSKAEKYYQIRCSGPGPLPYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDPII 518

Qy 493 LNETKFWYQMLPDPHFDKSKYPLLLDVYAGPCSKADTVFRLNWTYLASTENIIVASF 552

Db 519 LNETKFWYQMLPDPHFDKSKYPLLLDVYAGPCSKADTVFRLNWTYLASTENIIVASF 578

Qy 553 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAARQFSKMGFVDNKRRIAGWSYGGYVTSM 612

Db 579 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAARQFSKMGFVDNKRRIAGWSYGGYVTSM 638

Qy 613 VLGSQGVFKCGIAVAPVSRWEYVDSVYTERYMGSLPTPEDNLDHYNSTVMSRAENFKOV 672

Db 639 VLGSQGVFKCGIAVAPVSRWEYVDSVYTERYMGSLPTPEDNLDHYNSTVMSRAENFKOV 698

Qy 673 EYLLIHGTADDNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIIASSTAHOHYTHMSHF 732

Db 699 EYLLIHGTADDNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIIASSTAHOHYTHMSHF 758

Qy 733 IKQCFSLP 740

Db 759 IKQCFSLP 766

RESULT 24

AAO15555

ID AAO15555 standard; protein; 766 AA.

XX

AC AAO15555;

XX

DT 24-OCT-2002 (first entry)

XX

DE Human dipeptidyl peptidase IV (DPP IV).

XX

KW Human; angiodemic condition; angiotensin converting enzyme; ACE;

XX

KW vasopeptidase inhibitor; dipeptidyl peptidase IV; aminopeptidase P;

XX

KW DPP IV; aminopeptidase P; APP; hypertension; diabetes; cardiac disease;

XX

XX renal disease; enzyme.

OS Homo sapiens.

XX

XX WO200259343-A2.

PN

XX

Qy 613 VLGGSGVFKGCIAGVAPSRWEYDVSVTERYMGLEPTEDNLDHYRNSVMSRAENPKQV 672
 Db |||||||
 Qy 639 VLGGSGVFKGCIAGVAPSRWEYDVSVTERYMGLEPTEDNLDHYRNSVMSRAENPKQV 698
 Db |||||||
 Qy 673 EYLLIHGTADDNVHFQQAQISKALVDVGVDFOAMWYTDDEHGIASSTAHQHIYTHMSHF 732
 Db |||||||
 Qy 699 EYLLIHGTADDNVHFQQAQISKALVDVGVDFOAMWYTDDEHGIASSTAHQHIYTHMSHF 758
 Qy 733 IKQCFSLP 740
 Db |||||||
 Qy 759 IKQCFSLP 766
 Db |||||||
 RESULT 22
 ID ADO40240 standard; protein; 736 AA.
 AC ADO40240;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Human DPP-IV extracellular domain protein SEQ ID NO:2.
 XX
 KW crystal; mammalian dipeptidyl-peptidase IV extracellular domain;
 KW dipeptidyl-peptidase IV extracellular domain;
 KW DPP-IV extracellular domain; three-dimensional structure; antidiabetic;
 KW anorectic; cytostatic; type II diabetes; type II diabetes; IGT; obesity;
 KW cancer; human; DPP-IV; enzyme; protein co-ordinate data; EC 3.4.14.5.
 XX
 OS Homo sapiens.
 XX
 PN EPI422293-A1.
 XX
 PD 26-MAY-2004.
 XX
 PF 17-NOV-2003; 2003EP-00026169.
 XX
 PR 25-NOV-2002; 2002EP-00026367.
 XX
 PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
 XX
 PI Hennig M, Loeffler BM, Thoma R;
 XX
 DR WPI; 2004-413363/39.
 DR N-PSDB; ADO40239.
 XX
 PT New crystal of an extracellular domain of mammalian dipeptidyl-peptidase
 PT IV (DPP-IV) useful for identifying or designing inhibitors of DPP-IV
 PT activity.
 XX
 PS Claim 31; SEQ ID NO 2; 215pp; English.
 XX
 CC The present invention describes a crystal (I) of the extracellular domain
 CC of mammalian dipeptidyl-peptidase (DPP)-IV (EC 3.4.14.5). Also described:
 CC (1) a co-crystal of the extracellular domain of mammalian DPP-IV and a
 CC ligand bound to its active site; (2) a co-crystal of the extracellular
 CC domain of mammalian DPP-IV and a ligand bound to an allosteric binding
 CC site; (3) a co-crystal of the extracellular domain of mammalian DPP-IV
 CC and HgCl₂; (4) crystallising (M1) mammalian DPP-IV; (5) co-crystallising
 CC (M2) mammalian DPP-IV and an active site ligand; (6) a crystal produced
 CC by (M1) and (M2); (7) determining the three-dimensional structure of a
 CC crystallised extracellular domain of mammalian DPP-IV to a resolution of
 CC 3.5-2.1 angstrom or better; (8) a machine-readable data storage medium
 CC comprising a data storage material encoded with machine readable data
 CC which, when using a machine programmed with instructions for using the
 CC data, displays a graphical three-dimensional representation of a molecule
 CC or molecular complex comprising at least a portion of the extracellular
 CC domain of mammalian DPP-IV comprising a fully defined sequence (SEQ ID
 CC NO:2, S1) of 736 amino acids, where the extracellular domain comprising
 CC the ligand binding active site being defined by a set of points having a
 CC root mean square deviation of less than about 1.5 angstrom from points
 CC representing the backbone atoms of the amino acids as represented by
 CC structure coordinates as given in the specification; (9) a compound (II)

CC identified by using (I); (10) a pharmaceutical composition (III)
 CC comprising (I) and a carrier; (11) an isolated nucleic acid sequence (IV)
 CC encoding the soluble extracellular domain of DPP-IV comprising a fully
 CC defined sequence (SEQ ID NO:1, S2) of 2211 nucleotides; (12) a nucleic
 CC acid construct (V) comprising an expression vector and (IV); (13) a host
 CC cell (VI) transformed with (V); (14) producing the soluble extracellular
 CC domain of DPP-IV, involves culturing (VI) under conditions permitting the
 CC expression of the soluble extracellular domain of DPP-IV by (VI); and
 CC (15) a polypeptide comprising the soluble extracellular domain of (S1).
 CC DPP-IV has antidiabetic, anorectic and cytostatic activities. (I) is
 CC useful for identifying a compound that interacts with DPP-IV. The
 CC compound interacts with the active site of DPP-IV. The compound is an inhibitor
 CC of DPP-IV activity. (I) is useful for the identification and/or design of
 CC inhibitors of DPP-IV activity. (II) is useful as a therapeutic active
 CC substance, in particular for the treatment of diabetes type I, diabetes
 CC type II, IGT, obesity and cancer. (II) is useful for the manufacture of a
 CC medicament for the treatment of above mentioned disease. The present
 CC sequence represents the extracellular domain of human DPP-IV, which is
 CC used in the exemplification of the present invention.
 XX
 SQ Sequence 736 AA;

Query Match 97.8%; Score 3933; DB 8; Length 736;
 Best Local Similarity 99.9%; Pred No. 0;
 Matches 72; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 13 SRKTYTLTDYLNKNTYRLKLSLRWISDHEYLKQENNLVFNAYEYGNSSVFLENSTDEF 72
 Db |||||||
 Qy 73 GHSINDYSISPDGQFILLENNYKQWRHSYTSYDIYDLNKRQLITERTPNTQWTWS 132
 Db |||||||
 Qy 69 GHSINDYSISPDGQFILLENNYKQWRHSYTSYDIYDLNKRQLITERTPNTQWTWS 128
 Qy 133 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTVEEVSAYSALWNSP 192
 Db |||||||
 Qy 129 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTVEEVSAYSALWNSP 188
 Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLSQYPTKTVRVPYPKAGAVNPTKFFVNTDSLSS 252
 Db |||||||
 Qy 189 NGTFLAYAQFNDTEVPLIEYSFYSDESLSQYPTKTVRVPYPKAGAVNPTKFFVNTDSLSS 248
 Qy 253 VTNATSIQTAPASMLIGDHYLCDVWATQERISLQWLRIQNYSVMDICDYDESSGRWN 312
 Db |||||||
 Qy 249 VTNATSIQTAPASMLIGDHYLCDVWATQERISLQWLRIQNYSVMDICDYDESSGRWN 308
 Qy 313 CLVARQHIEMSTTGWGRFRPSPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 372
 Db |||||||
 Qy 309 CLVARQHIEMSTTGWGRFRPSPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 368
 Qy 373 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
 Db |||||||
 Qy 369 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLDYTKVTCLSCELNPERCQYYS 428
 Qy 433 VFSKKAAYQLRCSGFLPLYLTHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 492
 Db |||||||
 Qy 429 VFSKKAAYQLRCSGFLPLYLTHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 488
 Qy 493 LNETKFWYQMLPPHFDKSKYPLLLDVVAGPCSQKADTVFRLNWTATYLASTENIIVASFP 552
 Db |||||||
 Qy 489 LNETKFWYQMLPPHFDKSKYPLLLDVVAGPCSQKADTVFRLNWTATYLASTENIIVASFP 548
 Qy 553 DGRSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVNDKRIAIWGSYGGYVTSM 612
 Db |||||||
 Qy 549 DGRSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVNDKRIAIWGSYGGYVTSM 608
 Qy 613 VLGGSGVFKGCIAGVAPSRWEYDVSVTERYMGLEPTEDNLDHYRNSVMSRAENPKQV 672
 Db |||||||
 Qy 609 VLGGSGVFKGCIAGVAPSRWEYDVSVTERYMGLEPTEDNLDHYRNSVMSRAENPKQV 668
 Qy 673 EYLLIHGTADDNVHFQQAQISKALVDVGVDFOAMWYTDDEHGIASSTAHQHIYTHMSHF 732
 Db |||||||

QY 613 VLGSQGVKCGIAVAPVSRWEYDVSVTERYMGLEPTPEDNLDHYRNVSTVMSRAENFKQV 672
 D 639 VLGSQGVKCGIAVAPVSRWEYDVSVTERYMGLEPTPEDNLDHYRNVSTVMSRAENFKQV 698
 QY 673 EYLLHGTADDNVHFQQAQISKALVDGVDFQAMWYTDDEHGTASSTAHQHIYTHMSHF 732
 D 699 EYLLHGTADDNVHFQQAQISKALVDGVDFQAMWYTDDEHGTASSTAHQHIYTHMSHF 758
 QY 733 IKQCFSLP 740
 D 759 IKQCFSLP 766
 RESULT 21
 AEB94223
 ID AEB94223 standard; protein; 766 AA.
 XX
 AC AEB94223;
 XX
 XX 06-OCT-2005 (first entry)
 DE CD26/dipeptidyl peptidase IV (DPPIV) SEQ ID NO:66.
 XX
 KW immune inhibition; fibroblast activation protein alpha dimer;
 KW FAP alpha dimer; guillain barre syndrome; antiinflammatory; cns-gen.;
 KW immune disorder; neurological disease; autoimmune disease;
 KW immunosuppressive; graft versus host disease; transplant rejection;
 KW endotoxic shock; osteoarthritis; antiarthritic; osteopathic;
 KW musculoskeletal disease; allergy; antiallergic; asthma; antiasthmatic;
 KW inflammation; respiratory disease; atherosclerosis; antiarteriosclerotic;
 KW cardiovascular disease; metabolic disorder; hashimoto disease;
 KW antithyroid; endocrine disease; inflammatory bowel disease;
 KW antinflammatory; gastrointestinal-gen.; gastrointestinal disease;
 KW rheumatoid arthritis; antirheumatic; multiple sclerosis; neuroprotective;
 KW autoimmune hepatitis; antiinflammatory; hepatotropic;
 KW systemic lupus erythematosus; dermatological; dermatological disease;
 KW uveitis; ophthalmological; autoimmune hemolytic anemia; antianemic;
 KW hematological disease; rheumatic fever; antipyretic; Crohns disease;
 KW psoriasis; antipsoriatic; graves disease; antithyroid;
 KW respiratory syncytial virus infection; respiratory-gen.; virucide;
 KW CD26 dipeptidyl peptidase IV; DPPIV.
 XX
 OS Homo sapiens.
 OS
 PN WO2005071073-A1.
 XX
 PD 04-AUG-2005.
 XX
 PF 10-JAN-2005; 2005WO-US000709.
 XX
 PR 09-JAN-2004; 2004US-0535577P.
 XX
 XX (POIN-) POINT THERAPEUTICS INC.
 PA
 XX Mclean PA, Jones B, Miller GT, Jesson MI;
 PI
 XX WPI; 2005-564220/57.
 DR
 XX
 PT Down-regulating an immune response comprises administering to a subject
 PT in need a fibroblast activation protein (FAP) alpha dimer enzyme in an
 PT amount effective to down-regulate an immune response.
 XX
 PS Disclosure; SEQ ID NO 66; 177pp; English.
 XX
 CC The invention relates to a method of down-regulating an immune response,
 CC which comprises administering to a subject a fibroblast activation
 CC protein (FAP) alpha dimer enzyme in an amount effective to down-regulate
 CC an immune response. Also included are the following: a composition
 CC comprising a FAP alpha dimer enzyme in a pharmaceutically acceptable
 CC carrier, where the composition is sterile and lacks an adjuvant; a
 CC composition comprising a FAP alpha dimer enzyme in a pharmaceutically
 CC acceptable carrier, and a non-adjuvant second agent; a composition
 CC comprising a FAP alpha dimer enzyme comprising an amino acid substitution

CC of A657D; and a composition comprising a FAP alpha dimer enzyme lacking
 CC amino acids 269-448 and comprising amino acids 269-448 from mouse FAP.
 CC The method further comprises administering to the subject a second agent.
 CC The second agent is an anti-inflammatory agent, immunosuppressant, or
 CC anti-infective agent such as antibacterial, antiviral, antifungal, anti-
 CC parasitic or anti-mycobacterial agent. The FAP alpha dimer enzyme is wild
 CC type FAP alpha dimer enzyme. The FAP alpha dimer enzyme is a truncation
 CC mutant. The FAP alpha dimer enzyme is a fusion or chimera protein. The
 CC FAP alpha dimer enzyme is a heterodimer of a FAP alpha monomer and a
 CC DPPIV/CD26 monomer. The FAP alpha dimer enzyme comprises an amino acid
 CC substitution relative to wild type FAP alpha dimer. The amino acid
 CC domain, or an N-linked glycosylation site and alters disulfide bond
 CC formation. The immune response is an especially an IL-1 mediated
 CC condition, abnormal immune response selected from inflammation,
 CC autoimmune disease, sepsis, graft versus host disease, transplant
 CC rejection, toxic shock syndrome, allergy, asthma, atherosclerosis,
 CC osteoarthritis, and Guillain-Barre's syndrome. The abnormal immune
 CC response is subsequent to an infection, such as an RSV infection. The
 CC autoimmune disease is selected from C, autoimmune thyroiditis, systemic
 CC lupus erythematosus (SLE), uveitis, hemolytic anemias, Graves' disease,
 CC Crohn's disease, Guillain-Barre's syndrome, psoriasis, rheumatic fever,
 CC myasthenia gravis, glomerulonephritis, autoimmune hepatitis and multiple
 CC sclerosis. The subject does not have cancer or a predisposition to
 CC cancer. The present sequence represents the amino acid sequence of human
 CC CD26/dipeptidyl peptidase IV (DPPIV).
 XX
 SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 9; Length 766;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 SRKYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNLVFNAYGNSVPLENSTFDEF 72
 DB 39 SRKYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNLVFNAYGNSVPLENSTFDEF 98
 QY 73 GHSINDYSISPDGQFILLVYVVKQWRHSYASYDIYDLNKRQLTEERIPIINTQVTVWS 132
 DB 99 GHSINDYSISPDGQFILLVYVVKQWRHSYASYDIYDLNKRQLTEERIPIINTQVTVWS 158
 QY 133 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTVEEVEFSAYSLWNSP 192
 DB 159 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTVEEVEFSAYSLWNSP 218
 QY 193 NGTFLAYAQFNDTEVPLIEYFSYDESLOYPKTVRPYPKAGAVNPTVKFFVNTDSLSS 252
 DB 219 NGTFLAYAQFNDTEVPLIEYFSYDESLOYPKTVRPYPKAGAVNPTVKFFVNTDSLSS 278
 QY 253 VTNATSIQITAPASMLIGDHVLCVTVWATQBRISLQWLRRRINYNSVMDICDYDESSGRWN 312
 DB 279 VTNATSIQITAPASMLIGDHVLCVTVWATQBRISLQWLRRRINYNSVMDICDYDESSGRWN 338
 QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKCTFT 372
 DB 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKCTFT 398
 QY 373 KGTWEVIGIEALTSYLYVINSNEYKMGPGGRNLYKQLSDYTKVTCLSCELNPERCOYYS 432
 DB 399 KGTWEVIGIEALTSYLYVINSNEYKMGPGGRNLYKQLSDYTKVTCLSCELNPERCOYYS 458
 QY 433 VSFSKEAKYYQLRCSGPGGLPLYTLTHSSVNDKGLRVLEDNLSALDKMLQNVQMPSSKLDFTI 492
 DB 459 VSFSKEAKYYQLRCSGPGGLPLYTLTHSSVNDKGLRVLEDNLSALDKMLQNVQMPSSKLDFTI 518
 QY 493 LNETKFWQMIPLPHFDKSKYPLLLDYVAGCQKADTVFRLNWTATYLASTENIIVASF 552
 DB 519 LNETKFWQMIPLPHFDKSKYPLLLDYVAGCQKADTVFRLNWTATYLASTENIIVASF 578
 QY 553 DGRSGYQGDKIMHAINRRRLGTFFVEDQIEAARQFSKMGFVNDKRIAIWGSYGGYVTSM 612
 DB 579 DGRSGYQGDKIMHAINRRRLGTFFVEDQIEAARQFSKMGFVNDKRIAIWGSYGGYVTSM 638

```
Db 39 SRKTTTLTKNTYRLKLSLRWISDHEYLKQENNILVFNAEYGNSSVFLNSTPDEF 98
Qy 73 GHSINDYSIPDQFILLKYVVKWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVWS 132
Db 99 GHSINDYSIPDQFILLKYVVKWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVWS 158
Qy 133 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWWYEEVFSAYSALWWS 192
Db 159 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWWYEEVFSAYSALWWS 218
Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRPYPKAGAVNPTKFFVNTDSLSS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRPYPKAGAVNPTKFFVNTDSLSS 278
Qy 253 VTNATSIQITAPASMLIGDHYLCVDTWATQERISLOWLRRIQNYVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHYLCVDTWATQERISLOWLRRIQNYVMDICDYDESSGRWN 338
Qy 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICYFQIDKKDCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICYFQIDKKDCTFIT 398
Qy 373 KGTWEVIGIEALTSDYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
Db 399 KGTWEVIGIEALTSDYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458
Qy 433 VSPSKEAKYQOLRCGPGPLPYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 492
Db 459 VSPSKEAKYQOLRCGPGPLPYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 518
Qy 493 LNETKFWYQMLPPHFDKSKYPLLLDVTYAGPCSQKADTVFRLNWTATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVTYAGPCSQKADTVFRLNWTATYLASTENIIVASF 578
Qy 553 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAARQFSKMGFVDNKRKRIAIWGSYGGYVTS 612
Db 579 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAARQFSKMGFVDNKRKRIAIWGSYGGYVTS 638
Qy 613 VLGSAGVFKGCIAPVSRWEYDVSVYTERYMGILPTPEDNLDHYRNSVMSRAENFKQV 672
Db 639 VLGSAGVFKGCIAPVSRWEYDVSVYTERYMGILPTPEDNLDHYRNSVMSRAENFKQV 698
Qy 673 EYLLIHGTADDNVHFQSAQISKALVDVGVDFOAMWYTDDEHGIASSTAHOHIITHMSHF 732
Db 699 EYLLIHGTADDNVHFQSAQISKALVDVGVDFOAMWYTDDEHGIASSTAHOHIITHMSHF 758
Qy 733 IKQCFSLP 740
Db 759 IKQCFSLP 766
```

RESULT 20

ADZ14038
ID ADZ14038 standard; protein; 766 AA.

XX AC ADZ14038;

XX AC ADZ14038;

DT 16-JUN-2005 (first entry)

XX DE Human dipeptidyl peptidase IV protein.

XX DE diabetes; antidiabetic; endocrine disease; gastrointestinal disease;
KW metabolic disorder; dipeptidyl peptidase IV; CD26; enzyme.

XX OS Homo sapiens.

XX PN US2005074805-A1.

XX XX 07-APR-2005.

PD 28-SEP-2004; 2004US-00952459.

XX PF

XX XX

PR 03-OCT-2003; 2003US-0508699P.
XX (HOFF) HOFFMANN LA ROCHE INC.
PA Kochan JP, Martin ML, Rosinski JA;
PI WPI; 2005-283780/29.
XX N-PSDB; ADZ14037.
DR REFSEQ; NP_001926.
PT Diagnosing pre-diabetes, diabetes or susceptibility to diabetes, by
PT obtaining biological sample, and detecting or measuring level of
PT polypeptide marker comprising polypeptide e.g. vascular endothelial
PT growth factor B, apolipoprotein D.
XX Claim 1; SEQ ID NO 18; 66pp; English.
PS The present invention relates to a method for diagnosing of pre-diabetes,
CC diabetes or susceptibility to diabetes. The method involves obtaining a
CC biological sample and detecting or measuring the level of a polypeptide
CC marker, such as vascular endothelial growth factor B or apolipoprotein D.
CC The invention is useful for treating diabetes and pre-diabetes. The
CC present sequence is the human dipeptidyl peptidase IV (DPP4, DPP4)
CC protein. Dipeptidyl peptidase IV is also known as CD26, ADCP2, TP103,
CC ADABP; adenosine deaminase complexing protein 2 and Tcell activation
CC antigen CD26.
XX SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 9; Length 766;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 SRKTYTLTKNTYRLKLSLRWISDHEYLKQENNILVFNAEYGNSSVFLNSTPDEF 72
Db 39 SRKTYTLTKNTYRLKLSLRWISDHEYLKQENNILVFNAEYGNSSVFLNSTPDEF 98
Qy 73 GHSINDYSIPDQFILLKYVVKWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVWS 132
Db 99 GHSINDYSIPDQFILLKYVVKWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVWS 158
Qy 133 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWWYEEVFSAYSALWWS 192
Db 159 PVGHKLAYVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWWYEEVFSAYSALWWS 218
Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRPYPKAGAVNPTKFFVNTDSLSS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRPYPKAGAVNPTKFFVNTDSLSS 278
Qy 253 VTNATSIQITAPASMLIGDHYLCVDTWATQERISLOWLRRIQNYVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHYLCVDTWATQERISLOWLRRIQNYVMDICDYDESSGRWN 338
Qy 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICYFQIDKKDCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICYFQIDKKDCTFIT 398
Qy 373 KGTWEVIGIEALTSDYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
Db 399 KGTWEVIGIEALTSDYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458
Qy 433 VSPSKEAKYQOLRCGPGPLPYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 492
Db 459 VSPSKEAKYQOLRCGPGPLPYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 518
Qy 493 LNETKFWYQMLPPHFDKSKYPLLLDVTYAGPCSQKADTVFRLNWTATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVTYAGPCSQKADTVFRLNWTATYLASTENIIVASF 578
Qy 553 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAARQFSKMGFVDNKRKRIAIWGSYGGYVTS 612
Db 579 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAARQFSKMGFVDNKRKRIAIWGSYGGYVTS 638

KW Antinflammatory; Immune disorder; Dermatological; Immunosuppressive;
KW Antirheumatic; Antiarthritic; Osteopathic; Hemostatic; Antianemic;
KW Antithyroid; Antidiabetic; Nephrotropic; CNS-Gen.; Hepatotropic;
KW Virucide; Gastrointestinal-Gen.; Antipsoriatic; Antiasthmatic;
XX Antiallergic; ds; Gene; diagnosis.
OS Homo sapiens.
XX WO2005016962-A2.
XX PD 24-FEB-2005.
XX PF 11-AUG-2004; 2004WO-US026249.
XX PR 11-AUG-2003; 2003US-0493546P.
XX PA (GETH) GENENTECH INC.
XX PI Abbas A, Clark H, Ouyang W, Williams MP, Wood WI, Wu TD;
XX WPI; 2005-182330/19.
XX PT New nucleic acid encoding PRO polypeptide, useful for diagnosing and
PT treating an immune related disorder, e.g. systemic lupus erythematosus,
PT rheumatoid arthritis, osteoarthritis, thyroiditis, or diabetes mellitus.
XX PS Claim 8; SEQ ID NO 967; 158pp; English.
XX CC The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. The polypeptide, agonist or an antagonist, antibody,
CC composition, and method are useful for diagnosing and treating an immune
CC related disorder, e.g. systemic lupus erythematosus, rheumatoid
CC arthritis. The present sequence represents a DNA encoding a PRO
XX polypeptide.
SQ Sequence 766 AA;
Query Match 98.0%; Score 3939; DB 9; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 SRKTYTLTDYLNKTYRLKLSLRWISDHELYLKQENNLVFNARYGNSVFLNSTFDEF 72
DB 39 SRKTYTLTDYLNKTYRLKLSLRWISDHELYLKQENNLVFNARYGNSVFLNSTFDEF 98
QY 73 GHSINDYSTPDGQFILLLEYNVKKWRHSYASYDIYDLNKKQLITEERIPNNTQVWTWS 132
DB 99 GHSINDYSTPDGQFILLLEYNVKKWRHSYASYDIYDLNKKQLITEERIPNNTQVWTWS 158
QY 133 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWMYEEVFSYALSALWSP 192
DB 159 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWMYEEVFSYALSALWSP 218
QY 193 NGTFLLAYAQFNDTEVPLIEYSYDESLOYPKTVRPYPKAGAVNPTVKFFVNTDSLSS 252
DB 219 NGTFLLAYAQFNDTEVPLIEYSYDESLOYPKTVRPYPKAGAVNPTVKFFVNTDSLSS 278
QY 253 VTNATSIQITAPASMLIGHYLCDTVWATQERISIQWLRRIONYSVMDICDYDESSGRWN 312
DB 279 VTNATSIQITAPASMLIGHYLCDTVWATQERISIQWLRRIONYSVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTTGWGRPRPSEPHFTLDGNSFYKIIISNEEGRHICYFQIDKDCCTFIT 372
DB 339 CLVARQHIEMSTTGWGRPRPSEPHFTLDGNSFYKIIISNEEGRHICYFQIDKDCCTFIT 398
QY 373 KGTWEVIGIEALTSYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
DB 399 KGTWEVIGIEALTSYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458
QY 433 VSFSKEAKYQYLRCSGPGPLPLYTLHSSVNDKGLRVLEONSALDKMLQNVQMPESKLDFTI 492
DB 459 VSFSKEAKYQYLRCSGPGPLPLYTLHSSVNDKGLRVLEONSALDKMLQNVQMPESKLDFTI 518

QY 493 LNETKFWYQMLTPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATLASTENIIVASP 552
DB 519 LNETKFWYQMLTPPHFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATLASTENIIVASP 578
QY 553 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAAROFKMGFVDNKRKIAIATWGSYGGYVTSM 612
DB 579 DGRSGYQGDKIMHAINRRLGTFFVEDQIEAAROFKMGFVDNKRKIAIATWGSYGGYVTSM 638
QY 613 VLGSQGVFKCGIAVAPVSRWEYDVSVYTERYMGILPTPEDNLHDYRNSTVMSRAENFKQV 672
DB 639 VLGSQGVFKCGIAVAPVSRWEYDVSVYTERYMGILPTPEDNLHDYRNSTVMSRAENFKQV 698
QY 673 EYLLIHGTADDNVHFQOQAQISKALVDVGVDFOAMWYTDDEHGIASSAHQHIYTHMSHF 732
DB 699 EYLLIHGTADDNVHFQOQAQISKALVDVGVDFOAMWYTDDEHGIASSAHQHIYTHMSHF 758
QY 733 IKQCFSLP 740
DB 759 IKQCFSLP 766
RESULT 19
ADY16580
ID ADY16580 standard; protein; 766 AA.
XX AC ADY16580;
XX DT 05-MAY-2005 (first entry)
XX DE PRO polypeptide SEQ ID NO 2386.
XX KW Antiinflammatory; Immune disorder; Dermatological; Immunosuppressive;
KW Antirheumatic; Antiarthritic; Osteopathic; Hemostatic; Antianemic;
KW Antithyroid; Antidiabetic; Nephrotropic; CNS-Gen.; Hepatotropic;
KW Virucide; Gastrointestinal-Gen.; Antipsoriatic; Antiasthmatic;
KW Antiallergic; ds; Gene; diagnosis.
XX OS Homo sapiens.
XX PN WO2005016962-A2.
XX PD 24-FEB-2005.
XX PF 11-AUG-2004; 2004WO-US026249.
XX PR 11-AUG-2003; 2003US-0493546P.
XX PA (GETH) GENENTECH INC.
XX PI Abbas A, Clark H, Ouyang W, Williams MP, Wood WI, Wu TD;
XX WPI; 2005-182330/19.
XX PT New nucleic acid encoding PRO polypeptide, useful for diagnosing and
PT treating an immune related disorder, e.g. systemic lupus erythematosus,
PT rheumatoid arthritis, osteoarthritis, thyroiditis, or diabetes mellitus.
XX PS Claim 8; SEQ ID NO 2386; 158pp; English.
XX CC The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. The polypeptide, agonist or an antagonist, antibody,
CC composition, and method are useful for diagnosing and treating an immune
CC related disorder, e.g. systemic lupus erythematosus, rheumatoid
CC arthritis. The present sequence represents a DNA encoding a PRO
XX polypeptide.
SQ Sequence 766 AA;
Query Match 98.0%; Score 3939; DB 9; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 SRKTYTLTDYLNKTYRLKLSLRWISDHELYLKQENNLVFNARYGNSVFLNSTFDEF 72

Db 639 VLGGSGVFKCGIAVAPVSRWEYDVSVYTERYMGLTPTPEDNLHYNSTVMSRAENPKQV 698
 Qy 673 EYLLIHGTADDNVHFQQAQISKALVDVGVDFQAMWYTDHGHGASSTAHQHIIYTHMSHF 732
 Db 699 EYLLIHGTADDNVHFQQAQISKALVDVGVDFQAMWYTDHGHGASSTAHQHIIYTHMSHF 758
 Qy 733 IKQCFSLP 740
 Db 759 IKQCFSLP 766
 RESULT 17
 ADV25525
 ID ADV25525 standard; protein; 766 AA.
 AC
 XX ADV25525;
 DT 24-FEB-2005 (first entry)
 XX
 DE Human dipeptidyl-peptidase IV.
 KW Dipeptidyl-peptidase IV; DPP4; cardiovascular disease;
 KW dermatological disease; cancer; neoplasm; hematological disease;
 KW respiratory disease; Gastrointestinal disease; liver disease;
 KW metabolic disorder; Cardiovascular-Gen.; Endocrine-Gen.;
 KW Antiinflammatory; Gastrointestinal-Gen.; Gynecological;
 KW Neuroprotective; Cystostatic; Antiparkinsonian; Nootropic; Hepatotropic;
 KW Antiarrhythmic; Antiartherosclerotic; Antianemic; Antidiabetic;
 KW Dermatologic; Immunosuppressive; Muscular-Gen.; Antirheumatic;
 KW Antithrombotic; Antipeoriatic; Antiinfertility; Gene Therapy.
 XX
 OS Homo sapiens.
 PN W02004104216-A2.
 XX
 PD 02-DEC-2004.
 XX
 PF 12-MAY-2004; 2004WO-EP005071.
 XX
 PR 21-MAY-2003; 2003EP-00011481.
 XX
 PA (FARB) BAYER HEALTHCARE AG.
 XX
 PI Golz S, Brueggemeier U, Summer H;
 XX
 DR WPI; 2004-834301/82.
 DR N-PSDB; ADV25524.
 XX
 PT Use of dipeptidylpeptidase IV (DPP4) polypeptides or polynucleotides for
 PT screening therapeutic agents or for diagnosing or treating diseases
 PT associated with DPP4, e.g. cardiovascular, metabolic, inflammatory, or
 PT neurological disorders.
 XX
 PS Disclosure; SEQ ID NO 2; 128pp; English.
 CC
 CC The present sequence is the protein sequence of human dipeptidyl-
 CC peptidase IV (DPP4). The invention relates to novel disease associations
 CC of DPP4 polypeptides and polynucleotides and to novel methods of
 CC screening for therapeutic agents for the treatment of cardiovascular
 CC disorders, dermatological disorders, cancer, hematological disorders,
 CC respiratory diseases, gastrointestinal and liver diseases, urological
 CC disorders and metabolic diseases. Pharmaceutical compositions are
 CC provided for treatment of these diseases and disorders and comprise a
 CC DPP4 polypeptide, a DPP4 polynucleotide, or regulators of DPP4 or
 CC modulators of DPP4 activity. The therapeutic agent is preferably a small
 CC molecule, an RNA molecule, an antisense oligonucleotide, a polypeptide,
 CC an antibody or a ribozyme. The invention also provides methods of
 CC diagnosing diseases and disorders associated with DPP4 by measuring the
 CC amount of a DPP4 polynucleotide in a sample and comparing it with the
 CC amount in a sample from a healthy and/or diseased mammal. The diseases
 CC and disorders include Parkinson's disease, dementia, Alzheimer's disease,
 CC myocardial infarction, arrhythmias, atherosclerosis, anemia, eosinophilic
 CC disorders, leukemia, pancreatitis, Crohn's disease, inflammatory bowel

CC disease, diabetes, Cushing's syndrome, systemic lupus erythematosus,
 CC myasthenia gravis, rheumatoid arthritis, psoriasis, scleroderma, or
 CC infertility.
 XX
 SQ Sequence 766 AA;
 Query Match 98.0%; Score 3939; DB 8; Length 766;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 13 SRKTYTLTDYLNKTYRLKLSLRWISDHEYLKQENNLVFNAYSGNSVFLNSTPDEF 72
 Db 39 SRKTYTLTDYLNKTYRLKLSLRWISDHEYLKQENNLVFNAYSGNSVFLNSTPDEF 98
 Qy 73 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSYDIYDLNKRQLITBERIPNNTQMTWS 132
 Db 99 GHSINDYSISPDGQFILLEYNVYKQWRHSYTSYDIYDLNKRQLITBERIPNNTQMTWS 158
 Qy 133 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTCKEDIIYNGITDWWYEEVFSAYSAWMSP 192
 Db 159 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTCKEDIIYNGITDWWYEEVFSAYSAWMSP 218
 Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLOQPKTVRPYPKAGAVNPTVKFFVWNTDSLSS 252
 Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDESLOQPKTVRPYPKAGAVNPTVKFFVWNTDSLSS 278
 Qy 253 VTNATSIQITAPASMLIGDHYLDVWATQERISLOWLRRIQNVSVMDICDYDSSSGRW 312
 Db 279 VTNATSIQITAPASMLIGDHYLDVWATQERISLOWLRRIQNVSVMDICDYDSSSGRW 338
 Qy 313 CLVARQHIEMSTTGWGRPRPSPHFTLDGNSPYKIIISNEEGYRHCYFQIDKKDCTPIT 372
 Db 339 CLVARQHIEMSTTGWGRPRPSPHFTLDGNSPYKIIISNEEGYRHCYFQIDKKDCTPIT 398
 Qy 373 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSYTKVTKCLSCELNPERCQYYS 432
 Db 399 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSYTKVTKCLSCELNPERCQYYS 458
 Qy 433 VSFSKEAKYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDQMLQNVQMPSKLDFII 492
 Db 459 VSFSKEAKYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDQMLQNVQMPSKLDFII 518
 Qy 493 LNETKFWYQMLPPHFDKSKYKYPALLDVYAGPCSQKADTVFRLNWTATLASTENIIVASP 552
 Db 519 LNETKFWYQMLPPHFDKSKYKYPALLDVYAGPCSQKADTVFRLNWTATLASTENIIVASP 578
 Qy 553 DGRSGYQGDKIMHAINRRRLGTFEVEDQIEAARQFSKMGFVDNKRKIAIWGMSYGGYVTSM 612
 Db 579 DGRSGYQGDKIMHAINRRRLGTFEVEDQIEAARQFSKMGFVDNKRKIAIWGMSYGGYVTSM 638
 Qy 613 VLGGSGVFKCGIAVAPVSRWEYDVSVYTERYMGLTPTPEDNLHYNSTVMSRAENPKQV 672
 Db 639 VLGGSGVFKCGIAVAPVSRWEYDVSVYTERYMGLTPTPEDNLHYNSTVMSRAENPKQV 698
 Qy 673 EYLLIHGTADDNVHFQQAQISKALVDVGVDFQAMWYTDHGHGASSTAHQHIIYTHMSHF 732
 Db 699 EYLLIHGTADDNVHFQQAQISKALVDVGVDFQAMWYTDHGHGASSTAHQHIIYTHMSHF 758
 Qy 733 IKQCFSLP 740
 Db 759 IKQCFSLP 766
 RESULT 18
 ADV15161
 ID ADV15161 standard; protein; 766 AA.
 XX
 AC ADV15161;
 XX
 DT 05-MAY-2005 (first entry)
 XX
 DE PRO polypeptide SEQ ID NO 967.
 XX

Db 159 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWDVYEEVEFSAYSALWVSP 218
QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPKTVRVPYKAGAVNPTVKFFVNTDSLSS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPKTVRVPYKAGAVNPTVKFFVNTDSLSS 278
QY 253 VTNATSIQITAPASMLIGDHVLCVDTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHVLCVDTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKDKCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKDKCTFIT 398
QY 373 KGTWEVIGIEALTSYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
Db 399 KGTWEVIGIEALTSYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458
QY 433 VSFSKEAKYQLRCSGPGPLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 492
Db 459 VSFSKEAKYQLRCSGPGPLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 518
QY 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVPRLNWATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVPRLNWATYLASTENIIVASF 578
QY 553 DGRSGYQGDKIMHAINRRLLGTFEVEDQIEAARQFSKMGFVDNKRKIAIWGWSYGGVVTSM 612
Db 579 DGRSGYQGDKIMHAINRRLLGTFEVEDQIEAARQFSKMGFVDNKRKIAIWGWSYGGVVTSM 638
QY 613 VLGSAGVFKCGIAVAPVSRWEYDVSVTERYMGILPTPEDNLDHYRNSTVMSRAENFKOV 672
Db 639 VLGSAGVFKCGIAVAPVSRWEYDVSVTERYMGILPTPEDNLDHYRNSTVMSRAENFKOV 698
QY 673 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTDDEHGIIASSTAHOIYTHMSHF 732
Db 699 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTDDEHGIIASSTAHOIYTHMSHF 758
QY 733 IKQCFSLP 740
Db 759 IKQCFSLP 766

RESULT 16

ID ADU06688

XX ADU06688 standard; protein; 766 AA.

AC ADU06688;

XX 27-JAN-2005 (first entry)

DE Novel bronchial cancer-associated human protein SeqID914.

XX bronchial cancer; cytostatic; tumour-associated protein;

KW cancer detection; metastasis; tumour; human.

XX Homo sapiens.

XX DE10316701-A1.

PN 04-NOV-2004.

XX 09-APR-2003; 2003DE-01016701.

PF 09-APR-2003; 2003DE-01016701.

XX (HINZ/) HINZMANN B.

PA (HERM/) HERMANN K.

PA (CAST/) HEIDEN CASTANOS-VELEZ B.

XX Mennerich D, Bruemendorf T, Heiden E, Hermann K, Kinnemann H;

PI Li X, Roepcke S, Staub E, Hinzmann B, Rosenthal A, Pillarsky C;

XX

DR WPI; 2004-786403/78.
XX N-ESDB; ADU06201.

XX New nucleic acid, and derived proteins, useful for diagnosis of bronchial
PT cancer and in screening for therapeutic and diagnostic agents.

XX Claim 2; SEQ ID NO 914; 1381pp; German.

XX This invention relates to a novel isolated nucleic acid associated with
CC bronchial cancer comprising 489 defined sequences given in the
CC specification. The invention may be useful for the production of
CC compounds with a cytostatic activity through the inhibition of expression
CC or activity of tumour-associated proteins. The novel DNA sequences and
CC the proteins/peptides encoded by them are used for detecting bronchial
CC cancer or determining the risk of developing it and to screen for
CC specific binding partners of the DNA or protein sequences, where the
CC binding partners are potentially useful as agents for treating or
CC diagnosing bronchial cancer. The DNA or protein sequences can also be
CC used for prognosis, detection of metastases and for secondary treatment
CC (of tumours that have been stabilised or are no longer detectable).
CC Detecting abnormal expression of the DNA sequences provides early
CC diagnosis of bronchial cancers. The present sequence is that of a protein
CC encoded by a novel bronchial cancer-associated human gene sequence of the
CC invention.

XX Sequence 766 AA;

SQ Query Match 98.0%; Score 3939; DB 8; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKTYTLFDYLNQTVRLKYLRLWISDHEYLKQENNLVFNAEYGNSSVFLNSTFDF 72
Db 39 SRKTYTLFDYLNQTVRLKYLRLWISDHEYLKQENNLVFNAEYGNSSVFLNSTFDF 98

QY 73 GHSINDYSISPDGQFILLEYNVYQWRHSYASVDIYDLNKRQLITEIRIPNNTQVWTWS 132
Db 99 GHSINDYSISPDGQFILLEYNVYQWRHSYASVDIYDLNKRQLITEIRIPNNTQVWTWS 158

QY 133 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWDVYEEVEFSAYSALWVSP 192
Db 159 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWDVYEEVEFSAYSALWVSP 218

QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPKTVRVPYKAGAVNPTVKFFVNTDSLSS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYPKTVRVPYKAGAVNPTVKFFVNTDSLSS 278

QY 253 VTNATSIQITAPASMLIGDHVLCVDTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHVLCVDTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 338

QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKDKCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKDKCTFIT 398

QY 373 KGTWEVIGIEALTSYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
Db 399 KGTWEVIGIEALTSYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458

QY 433 VSFSKEAKYQLRCSGPGPLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 492
Db 459 VSFSKEAKYQLRCSGPGPLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDFII 518

QY 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVPRLNWATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVPRLNWATYLASTENIIVASF 578

QY 553 DGRSGYQGDKIMHAINRRLLGTFEVEDQIEAARQFSKMGFVDNKRKIAIWGWSYGGVVTSM 612
Db 579 DGRSGYQGDKIMHAINRRLLGTFEVEDQIEAARQFSKMGFVDNKRKIAIWGWSYGGVVTSM 638

QY 613 VLGSAGVFKCGIAVAPVSRWEYDVSVTERYMGILPTPEDNLDHYRNSTVMSRAENFKOV 672
XX

13	SRKTYTTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFAEYVGNSSVPLENSTPDEF	72
39	SRKTYTTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFAEYVGNSSVPLENSTPDEF	98
73	GHSINDYSISPDGQFILLLEYNVVKQRHSYTSYDIDLNKRQLITEERIINNQTQWTWS	132
99	GHSINDYSISPDGQFILLLEYNVVKQRHSYTSYDIDLNKRQLITEERIINNQTQWTWS	158
133	PVGHKLAYVWNDIYVKIEPNLPVRIITWTKGBDIINYGITDVIYBEVFSAYSALMWSP	192
159	PVGHKLAYVWNDIYVKIEPNLPVRIITWTKGBDIINYGITDVIYBEVFSAYSALMWSP	218
193	NGTFLAVAQFNDTEVPLIEYFSYDESIOYPKTVRVPYPKAGAVNPTVKFVNVNTDLSL	252
219	NGTFLAVAQFNDTEVPLIEYFSYDESIOYPKTVRVPYPKAGAVNPTVKFVNVNTDLSL	278
253	VTNATSIQITAPASMLGDHYLDCVWTATQBERISLQMLRRIQNTSVMDICDYDESSGRWN	312
279	VTNATSIQITAPASMLGDHYLDCVWTATQBERISLQMLRRIQNTSVMDICDYDESSGRWN	338
313	CLVARQHIEMSTTQVGRPRSPBPHFTLDGNSFYKIIISNEBGYRHCYFQIDKKDCTFIT	372
339	CLVARQHIEMSTTQVGRPRSPBPHFTLDGNSFYKIIISNEBGYRHCYFQIDKKDCTFIT	398
373	KGTEWVIGIEALTSDYLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPERCOVYS	432
399	KGTEWVIGIEALTSDYLYIISNEYKMGPGGRNLKYIQLSDYTKVTCLSCELNPERCOVYS	458
433	VSPSKEAKYQILRCGPGCLPLYTLHSSVNDKGLRVLEDNSALDKQLQNVQMPSKCLDFII	492
459	VSPSKEAKYQILRCGPGCLPLYTLHSSVNDKGLRVLEDNSALDKQLQNVQMPSKCLDFII	518
493	LNETHFWQMLLPHPDKSKYPLLLDVYAGPCSKADTVPLNNWATYLASTENIIVASF	552
519	LNETHFWQMLLPHPDKSKYPLLLDVYAGPCSKADTVPLNNWATYLASTENIIVASF	578
553	DGRSGYQGDKIMHAINRRLGTPEVEQIEAARQFSKMGFVNDKRIAIWGSYGYVTSM	612
579	DGRSGYQGDKIMHAINRRLGTPEVEQIEAARQFSKMGFVNDKRIAIWGSYGYVTSM	638
613	VLGSGSVFKCGIAVAPVSRWEYVDSYTYTRYMGLPTPEDNLHYRNSVTMSRAENPKQV	672
639	VLGSGSVFKCGIAVAPVSRWEYVDSYTYTRYMGLPTPEDNLHYRNSVTMSRAENPKQV	698
673	EYLLIHGTADNDNVHFQOSAOISKALVDVGVDFOAMWYTDSDHGFIASSTAQHIIYTHMSHP	732
699	EYLLIHGTADNDNVHFQOSAOISKALVDVGVDFOAMWYTDSDHGFIASSTAQHIIYTHMSHP	758
733	IKOCFSLP 740	
759	IKOCFSLP 766	

RESULT 15

RESOLUTION
ADP54458

ID ADP54458 standard: protein: 766 AA.

XX
XX

AC ADP54458;

XX

DT 18-NOV-2004 (first entry)

[illegible]

DE Human PRO protein sequence SEQ ID NO:434.

XX

KW human; PRO; immune related disease; inflammatory immune response;

KW haemostatic; hepatotropic; immunostimulant; immunosuppressive; muscular;
KW nephrotropic; neuroprotective; osteopathic; respiratory; vasotropic;
KW virucide; gene therapy.

OS Homo sapiens.

PN WO2004039956-A2.

13-MAY-2004.

28-OCT-2003: 2003WO-IIS034381-XX

XX
PR 29-OCT-2002. 2002US-0422472PXX
DA (CETH) CENTRECH INC[illegible]

PI Wood WI, Wu TD;
vv

DR WPI; 2004-376182/35.

• • • • •

PT and treating an immune related disease, e.g. systemic lupus

PT erythematosus, rheumatoid arthritis, diabetes mellitus or asthma and in

PT stimulating an immune response.

PS Claim 1; SEQ ID NO 434; 3009pp; English.

The present invention describes an isolated PRO nucleic acid (1). Also described: (1) a vector comprising (1); (2) a host cell comprising the vector of (1); (3) a process for producing a PRO polypeptides; (4) an isolated PRO polypeptide; (5) a heterologous molecule comprising the polypeptide of (4) fused to a heterologous amino acid sequence; (6) an antibody which specifically binds to a polypeptide of (4); (7) a composition of matter comprising a polypeptide of (4), an agonist or antagonist in combination with an antibody that binds to the polypeptide in combination with a carrier; (8) an article of manufacture comprising a container, a label on the container and a composition of matter of (7); (9) a method of treating an immune related disease in a mammal; (10) a method for determining the presence of a PRO polypeptide in a sample suspected of having the polypeptide; (11) a method of diagnosing an immune related disease or an inflammatory immune response in mammal; (12) a method of identifying a compound that inhibits or mimics the activity of or expression of a gene encoding a PRO polypeptide; and (13) a method of stimulating the immune response in a mammal. The PRO sequences have antiallergic, antianemic, antarthritic

Sequence 766 AA;

Query Match 98.0%: Score 3939: DB 8: Length 766:

Query Match 58.0%; SCORE 3939;
Best Local Similarity 100.0%; Pred. No. 0;

```

Best local similarity 100.0%, Freq. NO: 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0

```

OV 13 SRKTYTLTDYLNKNTYRLKLSLRWISDHEYLYKOEENILVFNAEYGNSSVFLENSTFDEF 72

QY 13 SKAIIIDIDILKWIIRKNTWISERWISDSHEILINQENNIUVFNATIGNSSVFDENSIFDEF / 2

DD 39 SKAIIILIDILANKIIRKNTISGRWISDHEIILIAQENNIILVFNAEIGNSSVFLENSIFDEF 98

QV 73 GHSINDYSISPDGOFILLEYNVVKOWRHSYTASYDIYDLNKROLITEERIPNNNTOWVWTS 132

db 99 GHSINDYSISPdGOFILL.EYVVKOWRHSYTA SYDIYDLNKROLITEERI PNNTOWVWS 158

PT Use of a CD26 composition, and a chemotherapeutic and/or a
PT radiotherapeutic agent for e.g. inhibiting the cell growth, inducing cell
PT cycle arrest, killing a cancer cell, treating cancer, or inducing tumor
PT regression or tumor necrosis.

XX Claim 23; Page 175-176; 182pp; English.

XX The specification describes a CD26 composition which, in conjunction with
XX chemotherapeutic or radiotherapeutic agents, is used for the treatment
XX and prevention of cancers. Expression of CD26 enhances the sensitivity of
XX the cancer cell to the chemotherapeutic or radiotherapeutic agent. CD26
XX is a dipeptidyl peptidase IV (DPP4). The chemotherapeutic agent is a
XX topoisomerase II inhibitor. The CD26 composition of the invention is
XX useful for inhibiting the growth of a cell, inducing cell cycle arrest in
XX a cell, killing a cancer cell, potentiating the effect of a
XX chemotherapeutic agent and/or a radiotherapeutic agent on a tumor cell,
XX inducing or enhancing apoptosis of a cancer cell, treating cancer, or
XX inducing tumor regression or tumor necrosis. The CD26 composition is
XX further useful for increasing topoisomerase II expression in a cell, for
XX activating an antigen-presenting cell, or for potentiating immune
XX responses of an animal. The present sequence represents a CD26 protein,
XX and is encoded by vectors which are used to produce compositions of the
XX invention.

SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 8; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKVTTLTDYKNTVRLKLSLRWISDHELYKQENNLVFNAYGNSVFLNSTFDEF 72
DB 39 SRKVTTLTDYKNTVRLKLSLRWISDHELYKQENNLVFNAYGNSVFLNSTFDEF 98
QY 73 GHSINDYSISDPGQFILLIYVYKWRHSYASYDIYDLNKRQLITEERI PNNTQVWTS 132
DB 99 GHSINDYSISDPGQFILLIYVYKWRHSYASYDIYDLNKRQLITEERI PNNTQVWTS 158
QY 133 PVGHKLAVWNNDIVKLEPNLPSRITWTGKEDIYNGITDWWYEEVFSAYSALWNSP 192
DB 159 PVGHKLAVWNNDIVKLEPNLPSRITWTGKEDIYNGITDWWYEEVFSAYSALWNSP 218
QY 193 NGTFLAYAQFNDTEVPLEIYSFYSDESLOQPKTVRPVYPKAGAVNPTVKFFVNTDSLSS 252
DB 219 NGTFLAYAQFNDTEVPLEIYSFYSDESLOQPKTVRPVYPKAGAVNPTVKFFVNTDSLSS 278
QY 253 VTNATSIQTAPASMLIGDHYLCYDTWATQBRISLQWLRRIQNYSVMDICDYDESSGRWN 312
DB 279 VTNATSIQTAPASMLIGDHYLCYDTWATQBRISLQWLRRIQNYSVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEGYRHICYFQDKKDCFTIT 372
DB 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEGYRHICYFQDKKDCFTIT 398
QY 373 KGTWEVIGIEALTSYLYIISNEYKMGPGRNLYKQLSDYTKVTCLSCELNPERCQYYS 432
DB 399 KGTWEVIGIEALTSYLYIISNEYKMGPGRNLYKQLSDYTKVTCLSCELNPERCQYYS 458
QY 433 VSFSEAKYQIURCSGPGPLPLTLHSSVNDKGLRVLEDNSALDKMLQNVQPSKKLDFII 492
DB 459 VSFSEAKYQIURCSGPGPLPLTLHSSVNDKGLRVLEDNSALDKMLQNVQPSKKLDFII 518
QY 493 LNETFWYQMIPLPHFDKSKYPLLLDDVYAGPCSKADTVFRLNWTYLASTENIIVASF 552
DB 519 LNETFWYQMIPLPHFDKSKYPLLLDDVYAGPCSKADTVFRLNWTYLASTENIIVASF 578
QY 553 DGRSGYQGDKIMHAINRLGTFEVEDQIEAARQFSKMGFVNDKRIAIWGSYGYVTSM 612
DB 579 DGRSGYQGDKIMHAINRLGTFEVEDQIEAARQFSKMGFVNDKRIAIWGSYGYVTSM 638
QY 613 VLGSSGVFKCIIAVAPSRWEYSDVYTERVNGLPTPEDNLDHVRNSTWMSRAENFKQV 672
DB 639 VLGSSGVFKCIIAVAPSRWEYSDVYTERVNGLPTPEDNLDHVRNSTWMSRAENFKQV 698

QY 673 EYLLIHGTADDNVHFQOQAISKALVDVGVDFOAMWYTDHGIASSTAHOIYTHMSHF 732
DB 699 EYLLIHGTADDNVHFQOQAISKALVDVGVDFOAMWYTDHGIASSTAHOIYTHMSHF 758

QY 733 IKQCFSLP 740
DB 759 IKQCFSLP 766

RESULT 14

ABM80355

ID ABM80355 standard; protein; 766 AA.

XX AC ABM80355;

XX 18-NOV-2004 (first entry)

XX Tumour-associated antigenic target (TAT) polypeptide PRO80881, SEQ:895.

XX Tumour-associated antigenic target; TAT; human; overexpression; cancer;

XX tumour; diagnosis; cell proliferative disorder; breast cancer;

XX colorectal cancer; lung cancer; ovarian cancer; liver cancer;

XX central nervous system cancer; bladder cancer; pancreatic cancer;

XX cervical cancer; melanoma; leukaemia; hybridisation probe;

XX chromosome identification; chromosome mapping; gene mapping;

XX gene therapy; cytostatic.

XX Homo sapiens.

XX WO2004030615-A2.

XX 15-APR-2004.

XX 29-SEP-2003; 2003WO-US028547.

XX 02-OCT-2002; 2002US-0414971P.

XX (GETH) GENENTECH INC.

XX Wu TD, Zhang Z, Zhou Y;

XX WPI; 2004-347921/32.

XX N-PSDB; ACN37783.

XX New tumor-associated antigenic target polypeptides and nucleic acids,

XX useful in preparing a medicament for treating or detecting a

XX proliferative disorder, e.g. breast, lung, colorectal, ovarian or

XX prostate cancer or tumor.

XX Claim 12; SEQ ID NO 895; 7273pp; English.

XX The invention relates to human tumour-associated antigenic target (TAT)

XX polypeptides, and their related nucleic acids. The TAT polypeptides are

XX overexpressed in cancer tissues compared to normal tissues, and may thus

XX serve as effective targets for the diagnosis and treatment of cancer in

XX mammals. The invention also relates to nucleic acid and polypeptide

XX sequences at least 80% identical to the TAT nucleic acids and

XX polypeptides; expression vectors and host cells comprising a TAT nucleic

XX acid; an antibody specific for a TAT polypeptide; a peptide or organic

XX molecule which binds to a TAT polypeptide; fusion proteins comprising a

XX TAT polypeptide; and methods and compositions for the treatment or

XX diagnosis of cancer in mammals. TAT polypeptides, nucleic acids,

XX antibodies, antagonists, binding molecules and compositions are useful

XX for diagnosing or treating a cell proliferative disorder associated with

XX colorectal cancer, lung cancer, ovarian cancer, liver cancer, bladder

XX cancer, pancreatic cancer, cervical cancer, cancers of the central

XX nervous system, melanoma and leukaemia. TAT nucleic acids may further be

XX used as hybridisation probes, in chromosome and gene mapping, in

XX chromosome identification and in gene therapy. The present sequence

XX represents a TAT polypeptide of the invention

XX

RESULT 12
 ADO71612
 ID ADO71612 standard; protein; 766 AA.
 XX
 AC ADO71612;
 DT 26-AUG-2004 (first entry)
 XX
 DE Amino acid sequence of a human CD26 protein.
 XX
 KW CD26; chemotherapeutic; radiotherapeutic; cancer; cell growth;
 KW dipeptidyl peptidase IV; DPPIV; topoisomerase II inhibitor;
 KW cell cycle arrest; tumour; tumour necrosis; immune response; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2004045497-A2.
 XX
 PD 03-JUN-2004.
 XX
 PF 15-MAY-2003; 2003WO-US015499.
 XX
 PR 17-MAY-2002; 2002US-0381606P.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Dang NH, Morimoto C;
 XX
 DR WPI; 2004-420511/39.
 DR N-PSDB; ADO71611, ADO71613.
 XX
 PT Use of a CD26 composition, and a chemotherapeutic and/or a
 PT radiotherapeutic agent for e.g. inhibiting the cell growth, inducing cell
 PT cycle arrest, killing a cancer cell, treating cancer, or inducing tumor
 PT regression or tumor necrosis.
 XX
 PS Claim 23; Page 151-153; 182pp; English.
 XX
 CC The specification describes a CD26 composition which, in conjunction with
 CC chemotherapeutic or radiotherapeutic agents, is used for the treatment
 CC and prevention of cancers. Expression of CD26 enhances the sensitivity of
 CC the cancer cell to the chemotherapeutic or radiotherapeutic agent. CD26
 CC is a dipeptidyl peptidase IV (DPPIV). The chemotherapeutic agent is a
 CC topoisomerase II inhibitor. The CD26 composition of the invention is
 CC useful for inhibiting the growth of a cell, inducing cell cycle arrest in
 CC a cell, killing a cancer cell, potentiating the effect of a
 CC chemotherapeutic agent and/or a radiotherapeutic agent on a tumour cell,
 CC inducing or enhancing apoptosis of a cancer cell, treating cancer, or
 CC inducing tumour regression or tumour necrosis. The CD26 composition is
 CC further useful for increasing topoisomerase II expression in a cell, for
 CC activating an antigen-presenting cell, or for potentiating immune
 CC responses of an animal. The present sequence represents a CD26 protein,
 CC and is encoded by vectors which are used to produce compositions of the
 CC invention.
 XX
 SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 8; Length 766;
 Best Local Similarity 100.0%; Pred. NO. 0;
 Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKTYTLTDYLNKTYRLKLSLRWISDHELYLKQENNILVFNAEYGNSSVPLENSPDEF 72
 DB 39 SRKTYTLTDYLNKTYRLKLSLRWISDHELYLKQENNILVFNAEYGNSSVPLENSPDEF 98
 QY 73 GHSINDYSISPDGQFILLENNYKWRHSYASDIYDLNKRQLITEERIPNNTQWTVWS 132
 DB 99 GHSINDYSISPDGQFILLENNYKWRHSYASDIYDLNKRQLITEERIPNNTQWTVWS 158
 QY 133 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWTYEEVFSAYSAWWS 192
 DB 159 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWTYEEVFSAYSAWWS 218

QY 193 NGTFLAYAQNDTEVPLIEYSFYSDLESLOYPKTVRVPYKAGAVNPTVKPFVNTDLS 252
 DB 219 NGTFLAYAQNDTEVPLIEYSFYSDLESLOYPKTVRVPYKAGAVNPTVKPFVNTDLS 278
 QY 253 VTNATSIQITAPASMLIGDHYLDCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWN 312
 DB 279 VTNATSIQITAPASMLIGDHYLDCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWN 338
 QY 313 CLVARQHIEMSTTGWGRFRPSPHFTLDGNSFPFKIISNEEGYRHICYFQIDKDCFTIT 372
 DB 339 CLVARQHIEMSTTGWGRFRPSPHFTLDGNSFPFKIISNEEGYRHICYFQIDKDCFTIT 398
 QY 373 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSDYTKVTCISCELNPERCQYS 432
 DB 399 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSDYTKVTCISCELNPERCQYS 458
 QY 433 VSFSEAKYQYLCRCGPGPLTYLTHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDPII 492
 DB 459 VSFSEAKYQYLCRCGPGPLTYLTHSSVNDKGLRVLEDNSALDKMLQNVQMPKSLDPII 518
 QY 493 LNETKFWQIMLPHPFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 552
 DB 519 LNETKFWQIMLPHPFDKSKYPLLLDVYAGPCSQKADTVFRLNWTATYLASTENIIVASF 578
 QY 553 DGRSGVQGGDKIMHAINRRIGTPEVEDQIEAARQFSKMGFVDNKRIAIMGWSYGVYVTS 612
 DB 579 DGRSGVQGGDKIMHAINRRIGTPEVEDQIEAARQFSKMGFVDNKRIAIMGWSYGVYVTS 638
 QY 613 VLGSGGVFKCGIAPVSRWEYDYSVYTERYMGSLPTPEDNLDRHNSVMSRAENFKQV 672
 DB 639 VLGSGGVFKCGIAPVSRWEYDYSVYTERYMGSLPTPEDNLDRHNSVMSRAENFKQV 698
 QY 673 EYLLIHGTADDNVHFQOQAISKALVDVGVDFOAMVYTTDEDHGIASSTAQHIIYTHMSHF 732
 DB 699 EYLLIHGTADDNVHFQOQAISKALVDVGVDFOAMVYTTDEDHGIASSTAQHIIYTHMSHF 758
 QY 733 IKOCFSLP 740
 DB 759 IKOCFSLP 766
 RESULT 13
 ADO71644
 ID ADO71644 standard; protein; 766 AA.
 XX
 AC ADO71644;
 DT 26-AUG-2004 (first entry)
 XX
 DE Amino acid sequence of a human CD26 protein.
 XX
 KW CD26; chemotherapeutic; radiotherapeutic; cancer; cell growth;
 KW dipeptidyl peptidase IV; DPPIV; topoisomerase II inhibitor;
 KW cell cycle arrest; tumour; tumour necrosis; immune response; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2004045497-A2.
 XX
 PD 03-JUN-2004.
 XX
 PF 15-MAY-2003; 2003WO-US015499.
 XX
 PR 17-MAY-2002; 2002US-0381606P.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Dang NH, Morimoto C;
 XX
 DR WPI; 2004-420511/39.
 DR N-PSDB; ADO71643.
 XX

Db 339 CLVARQHTEMSTTGWVGRFRPSEPHFTLDGNSFYKIIISNEGYRHCYFQIDKKDCTFT 398
Qy 373 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
Db 399 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458
Qy 433 VFSKAEKYYQLRCGPGGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKCLDFII 492
Db 459 VFSKAEKYYQLRCGPGGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKCLDFII 518
Qy 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVFRLNWTATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVFRLNWTATYLASTENIIVASF 578
Qy 553 DGRSGYOGDKIMHAINRRLGTFEVDQIEAARQFSKMGFVDNKRKIAIWGWSYGGYVTSM 612
Db 579 DGRSGYOGDKIMHAINRRLGTFEVDQIEAARQFSKMGFVDNKRKIAIWGWSYGGYVTSM 638
Qy 613 VLGSFGVFKCGIAVAPVSRWEYDVSVYTERYMGLTPTPEDNLDHYRNSTVMSRAENFKQV 672
Db 639 VLGSFGVFKCGIAVAPVSRWEYDVSVYTERYMGLTPTPEDNLDHYRNSTVMSRAENFKQV 698
Qy 673 EYLLIHGTADNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHOHIYTHMSHP 732
Db 699 EYLLIHGTADNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHOHIYTHMSHP 758
Qy 733 IKQCFSLP 740
Db 759 IKQCFSLP 766

RESULT 11
ADO19806
ID ADO19806 standard; protein; 766 AA.
XX
AC ADO19806;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human PRO polypeptide #365.
XX
KW Human; PRO; immune related disorder; systemic lupus erythematosus;
KW rheumatoid arthritis; osteoarthritis; juvenile chronic arthritis;
KW systemic sclerosis; Sjogren's syndrome; vasculitis; sarcoidosis;
KW autoimmune haemolytic anaemia; autoimmune thrombocytopenia; thyroiditis;
KW diabetes mellitus; renal disease; demyelinating disease;
KW central nervous system; peripheral nervous system;
KW demyelinating polyneuropathy; Guillain-Barre syndrome;
KW chronic inflammatory demyelinating polyneuropathy.
XX
OS Homo sapiens.
XX
PW WO2004043361-A2.
XX
PD 27-MAY-2004.
XX
PF 06-NOV-2003; 2003WO-US035268.
XX
PR 08-NOV-2002; 2002US-0425235P.
XX
PA (GETH) GENENTECH INC.
XX
PI Fong S, Dennis K, Clark H, Chiu H, Schoenfeld J, Williams PM;
PI Wood WI, Wu TD;
XX
XX WPI; 2004-420067/39.
DR N-PSDB; ADO19805.
XX
PT Novel PRO polypeptide e.g., PRO69614, PRO71106, or PRO86388 useful for
PT treating an immune related disorder such as systemic lupus erythematosus,
PT rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis or
PT spondyloarthropathy.
XX

PS Claim 7; SEQ ID NO 730; 1731pp; English.
XX
CC The invention relates to human PRO polypeptides and the polynucleotides
CC encoding them. The polypeptides and polynucleotides are useful for
CC treating and diagnosing immune related disorders in mammals. The immune
CC related disorders include systemic lupus erythematosus, rheumatoid
CC arthritis, osteoarthritis, juvenile chronic arthritis, systemic
CC sclerosis, Sjogren's syndrome, vasculitis, sarcoidosis, autoimmune
CC haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes
CC mellitus, immune-mediated renal disease, demyelinating diseases of the
CC central or peripheral nervous system, demyelinating polyneuropathy,
CC Guillain-Barre syndrome and chronic inflammatory demyelinating
CC polyneuropathy. This sequence represents a human PRO polypeptide of the
CC invention.
SQ Sequence 766 AA;
Query Match 98.0%; Score 3939; DB 8; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 13 SRKTYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFNAEYGNSSVFLNSTFDFE 72
Db 39 SRKTYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFNAEYGNSSVFLNSTFDFE 98
Qy 73 GHSINDYSISPDGQFILLEYNVYKQWRHSYTYASDIYDLNKRQLITEBRIPNNTQVWTWS 132
Db 99 GHSINDYSISPDGQFILLEYNVYKQWRHSYTYASDIYDLNKRQLITEBRIPNNTQVWTWS 158
Qy 133 PVGHKLAYVWNDIYVKIEPNLPSYRITWTCKEDIIYNGITDWDYEEVFSAYSALWWS 192
Db 159 PVGHKLAYVWNDIYVKIEPNLPSYRITWTCKEDIIYNGITDWDYEEVFSAYSALWWS 218
Qy 193 NGTFLAYAQFNDTEVPLIEYSFYSDSELYQPKTVRVPYKAGAVNPTVKFFVNTDSLS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDSELYQPKTVRVPYKAGAVNPTVKFFVNTDSLS 278
Qy 253 VTNATSIQITAPASMLIGDHYLDCVWTWATERISLQWLRRIONYSVMDCIDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHYLDCVWTWATERISLQWLRRIONYSVMDCIDYDESSGRWN 338
Qy 313 CLVARQHTEMSTTGWVGRFRPSEPHFTLDGNSFYKIIISNEGYRHCYFQIDKKDCTFT 372
Db 339 CLVARQHTEMSTTGWVGRFRPSEPHFTLDGNSFYKIIISNEGYRHCYFQIDKKDCTFT 398
Qy 373 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 432
Db 399 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYS 458
Qy 433 VFSKAEKYYQLRCGPGGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKCLDFII 492
Db 459 VFSKAEKYYQLRCGPGGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPKCLDFII 518
Qy 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVFRLNWTATYLASTENIIVASF 552
Db 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGPCSKADTVFRLNWTATYLASTENIIVASF 578
Qy 553 DGRSGYOGDKIMHAINRRLGTFEVDQIEAARQFSKMGFVDNKRKIAIWGWSYGGYVTSM 612
Db 579 DGRSGYOGDKIMHAINRRLGTFEVDQIEAARQFSKMGFVDNKRKIAIWGWSYGGYVTSM 638
Qy 613 VLGSFGVFKCGIAVAPVSRWEYDVSVYTERYMGLTPTPEDNLDHYRNSTVMSRAENFKQV 672
Db 639 VLGSFGVFKCGIAVAPVSRWEYDVSVYTERYMGLTPTPEDNLDHYRNSTVMSRAENFKQV 698
Qy 673 EYLLIHGTADNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHOHIYTHMSHP 732
Db 699 EYLLIHGTADNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHOHIYTHMSHP 758
Qy 733 IKQCFSLP 740
Db 759 IKQCFSLP 766

CC sequence is used in the exemplification of the present invention.

XX
SQ Sequence 766 AA;
Query Match 98.0%; Score 3939; DB 8; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 SRKTYTLTDYLNKTYRLKGLYSRLWISDHEYLKQENNLVFNAYGSSVFLNSTPDEF 72
DB 39 SRKTYTLTDYLNKTYRLKGLYSRLWISDHEYLKQENNLVFNAYGSSVFLNSTPDEF 98
QY 73 GHSINDYSISPDGQFILLLEYNVYKQWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVS 132
DB 99 GHSINDYSISPDGQFILLLEYNVYKQWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVS 158
QY 133 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWYBEVFSAYSALWSP 192
DB 159 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWYBEVFSAYSALWSP 218
QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLOQPKTVRVPYKAGAVNPTKFFVNTDSLSS 252
DB 219 NGTFLAYAQFNDTEVPLIEYSFYSDESLOQPKTVRVPYKAGAVNPTKFFVNTDSLSS 278
QY 253 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIQNSYVMDICDYDESSGRWN 312
DB 279 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIQNSYVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 372
DB 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 398
QY 373 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQISDYTKVTCISCLNPERCOYYS 432
DB 399 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQISDYTKVTCISCLNPERCOYYS 458
QY 433 VFSKEAKYQLRCSGFGLPLYTLHSSVNDKGLRVLEDNSALDQMLQNVQMPKCLDFII 492
DB 459 VFSKEAKYQLRCSGFGLPLYTLHSSVNDKGLRVLEDNSALDQMLQNVQMPKCLDFII 518
QY 493 LNETKFWYQMLPFPDKSKYPLLLDVYAGPCSQKADTVFRLNWTYLASTENIIVASF 552
DB 519 LNETKFWYQMLPFPDKSKYPLLLDVYAGPCSQKADTVFRLNWTYLASTENIIVASF 578
QY 553 DGRSGGYQGIKIHAINRRLGTPEVEDQIEAARQFSKMGFVNDKRIAIWWSVGGYVTSM 612
DB 579 DGRSGGYQGIKIHAINRRLGTPEVEDQIEAARQFSKMGFVNDKRIAIWWSVGGYVTSM 638
QY 613 VLGGSGVFKCGIAPVPSRWEYDVSVYTRYMGLPTPEDNLHYRNSTVMSRAENPKQV 672
DB 639 VLGGSGVFKCGIAPVPSRWEYDVSVYTRYMGLPTPEDNLHYRNSTVMSRAENPKQV 698
QY 673 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTTDHDGIASSTAHOHYTHMSHF 732
DB 699 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTTDHDGIASSTAHOHYTHMSHF 758
QY 733 IKQCPSLP 740
DB 759 IKQCPSLP 766

RESULT 10

AD019398
ID AD019398 standard; protein; 766 AA.
XX
AC AD019398;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human PRO polypeptide #164.
KW Human; PRO; immune related disorder; systemic lupus erythematosus;
KW rheumatoid arthritis; osteoarthritis; juvenile chronic arthritis;

KW systemic sclerosis; Sjogren's syndrome; vasculitis; sarcoidosis;
KW autoimmune haemolytic anaemia; autoimmune thrombocytopenia; thyroiditis;
KW diabetes mellitus; renal disease; demyelinating disease;
KW central nervous system; peripheral nervous system;
KW demyelinating polyneuropathy; Guillain-Barre syndrome;
KW chronic inflammatory demyelinating polyneuropathy.

XX Homo sapiens.

XX WO2004043361-A2.

XX 27-MAY-2004.

XX 06-NOV-2003; 2003WO-US035268.

XX 08-NOV-2002; 2002US-0425235P.

XX (GETH) GENENTECH INC.

XX Fong S, Dennis K, Clark H, Chiu H, Schoenfeld J, Williams PM;
XX Wood WI, Wu TD;

XX WPI; 2004-420067/39.

XX N-PSDB; ADOI9397.

XX Novel PRO polypeptide e.g., PRO69614, PRO71106, or PRO86388 useful for
XX treating an immune related disorder such as systemic lupus erythematosus,
XX rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis or
XX spondyloarthritis.

XX Claim 7; SEQ ID NO 328; 1731pp; English.

XX The invention relates to human PRO polypeptides and the polynucleotides
XX encoding them. The polypeptides and polynucleotides are useful for
XX treating and diagnosing immune related disorders in mammals. The immune
XX related disorders include systemic lupus erythematosus, rheumatoid
XX arthritis, osteoarthritis, juvenile chronic arthritis, systemic
XX sclerosis, Sjogren's syndrome, vasculitis, sarcoidosis, autoimmune
XX haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes
XX mellitus, immune-mediated renal disease, demyelinating diseases of the
XX central or peripheral nervous system, demyelinating polyneuropathy,
XX Guillain-Barre syndrome and chronic inflammatory demyelinating
XX polyneuropathy. This sequence represents a human PRO polypeptide of the
XX invention.

XX SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 8; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKTYTLTDYLNKTYRLKGLYSRLWISDHEYLKQENNLVFNAYGSSVFLNSTPDEF 72

DB 39 SRKTYTLTDYLNKTYRLKGLYSRLWISDHEYLKQENNLVFNAYGSSVFLNSTPDEF 98

QY 73 GHSINDYSISPDGQFILLLEYNVYKQWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVS 132

DB 99 GHSINDYSISPDGQFILLLEYNVYKQWRHSYTSYDIYDLNKRQLITEERIPNNTQWTVS 158

QY 133 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWYBEVFSAYSALWSP 192

DB 159 PVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWYBEVFSAYSALWSP 218

QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLOQPKTVRVPYKAGAVNPTKFFVNTDSLSS 252

DB 219 NGTFLAYAQFNDTEVPLIEYSFYSDESLOQPKTVRVPYKAGAVNPTKFFVNTDSLSS 278

QY 253 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIQNSYVMDICDYDESSGRWN 312

DB 279 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIQNSYVMDICDYDESSGRWN 338

QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 372

PT New crystal of dipeptidyl peptidase IV capable of analyzing its three-
PT dimensional structure, useful for designing, identifying, evaluating or
XX searching an effector of the dipeptidyl peptidase IV.

PS Claim 3; SEQ ID NO 2; 332pp; English.

XX The invention relates to a novel crystal of a dipeptidyl peptidase IV
CC (DPPIV) which is sufficient to ensure a resolution capable of analysing
CC its three-dimensional structure up to the side chain level by X-ray
CC crystallographic structural analysis. The crystal of the invention
CC demonstrates immunomodulatory, antidiabetic, antiinflammatory,
CC neuroprotective, antithyroid, antirheumatic, antiarthritic, anti-HIV and
CC cystostatic activities and may be useful for providing a three-dimensional
CC structural coordinate as the information for designing, identifying,
CC evaluating or searching for an effector of the dipeptidyl peptidase IV.
CC The effector may be useful as a modulatory agent of immune response and
CC as a therapeutic or prophylactic agent for diabetes, inflammation, AIDS
CC multiple sclerosis, Grave's disease, chronic rheumatoid arthritis, AIDS
CC or cancer. The current sequence is that of the human full-length colon
CC dipeptidyl peptidase IV (DPPIV) protein of the invention.

SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 8; Length 766;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKTYTLDTYKNTYLRKLYLRWISDHEYLKQENNLVFNAEYGNSSVFLNSTPDEF 72
DB 39 SRKTYTLDTYKNTYLRKLYLRWISDHEYLKQENNLVFNAEYGNSSVFLNSTPDEF 98
QY 73 GHSINDYSIPDQFILLFYNVVKQHRHSYASYDIYDLNKRQLITEIRIPNNTQVWTS 132
DB 99 GHSINDYSIPDQFILLFYNVVKQHRHSYASYDIYDLNKRQLITEIRIPNNTQVWTS 158
QY 133 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTVEEVSFSAISALWSP 192
DB 159 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKEDIYNGITDWTVEEVSFSAISALWSP 218
QY 193 NGTFLAYAQFNDETEPLLEYSPYSDLSQYPKTVRVPYKAGVNPVKFFVNTDSLSS 252
DB 219 NGTFLAYAQFNDETEPLLEYSPYSDLSQYPKTVRVPYKAGVNPVKFFVNTDSLSS 278
QY 253 VTNATSIQITAPASMLIGHYLCVDTWATQERISLQWLRRIQNSVMDICDYDESSGRWN 312
DB 279 VTNATSIQITAPASMLIGHYLCVDTWATQERISLQWLRRIQNSVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTGWGRPRPSEPHFTLDGNSFYKIIISNEGYRHI CYFQIDKKDCTFIT 372
DB 339 CLVARQHIEMSTGWGRPRPSEPHFTLDGNSFYKIIISNEGYRHI CYFQIDKKDCTFIT 398
QY 373 KGTWEVIGTEALTSYLYYISNEYKMGPGRNLYKIQSDYTKVTCLSCELPNRCQVYS 432
DB 399 KGTWEVIGTEALTSYLYYISNEYKMGPGRNLYKIQSDYTKVTCLSCELPNRCQVYS 458
QY 433 VSFSEAKYQYLRCSGPGIPLYTLHSSVNDKGLRVLEDSALDKMLQNVQMPSEKLDFTI 492
DB 459 VSFSEAKYQYLRCSGPGIPLYTLHSSVNDKGLRVLEDSALDKMLQNVQMPSEKLDFTI 518
QY 493 LNETKFWQIMILPHFDKSKYPLLLDDVYAGPCSKADTVFRLNWTYLASTENIIVASF 552
DB 519 LNETKFWQIMILPHFDKSKYPLLLDDVYAGPCSKADTVFRLNWTYLASTENIIVASF 578
QY 553 DGRSGSGYQGDKTIMHAINRLGTFEVEDQIEAARQFSKMGFVNDKRIATWGSYGGVVTSM 612
DB 579 DGRSGSGYQGDKTIMHAINRLGTFEVEDQIEAARQFSKMGFVNDKRIATWGSYGGVVTSM 638
QY 613 VLGSAGVFKCIGIAPVSRWEYSDYVTERYWGMLPTPEDNLDRHNSVWMSRAENFKQV 672
DB 639 VLGSAGVFKCIGIAPVSRWEYSDYVTERYWGMLPTPEDNLDRHNSVWMSRAENFKQV 698
QY 673 EYLLIHGTADDNVHFQOQSAQISKALVDVGVDFOAMWYTDDEHGIASSTAHOIYTHMSHP 732

Db 699 EYLLIHGTADDNVHFQOQSAQISKALVDVGVDFOAMWYTDDEHGIASSTAHOIYTHMSHP 758
QY 733 IKQCFSLP 740
DB 759 IKQCFSLP 766

RESULT 9

ADJ75313

ID ADJ75313 standard; protein; 766 AA.

XX ADJ75313;

XX 20-MAY-2004 (first entry)

XX Marker gene related amino acid sequence SEQ ID NO:565.

XX bronchial asthma; chronic obstructive pulmonary disease;

KW respiratory epithelial cell; interleukin-13; respiratory; antiasthmatic;

KW gene therapy; marker.

XX Homo sapiens.

XX EPI394274-A2.

XX 03-MAR-2004.

XX 04-AUG-2003; 2003EP-00254857.

XX 06-AUG-2002; 2002JP-00229312.

XX 20-MAR-2003; 2003JP-00077212.

XX (GENO-) GENOX RES INC.

XX Ohtani N, Sugita Y, Yamaya M, Kubo H, Nagai H, Izuhara K;

XX WPI; 2004-193155/19.

XX Testing for bronchial asthma or chronic obstructive pulmonary disease by
XX comparing the expression level of a marker gene in a biological sample
XX from a subject with the expression level of the gene in a sample from a
XX healthy subject.

XX Example 11; SEQ ID NO 565; 241pp; English.

XX The present invention describes a method of testing for bronchial asthma
XX or chronic obstructive pulmonary disease. The method comprises
XX determining the expression level of a marker gene in a biological sample
XX from a subject, comparing the expression level determined with the
XX expression level of the marker gene in a biological sample from a healthy
XX subject, and judging whether the subject has bronchial asthma or chronic
XX obstructive pulmonary disease. The marker gene comprises: (a) a group of
XX genes (S1) whose expression levels increase when respiratory epithelial
XX cells are stimulated with interleukin-13; or (b) a group of genes (S2)
XX whose expression levels decrease when respiratory epithelial cells are
XX stimulated with interleukin-13. Also described: (1) a reagent (1) for
XX testing for bronchial asthma or chronic obstructive pulmonary disease;
XX (2) a kit for screening for a candidate compound for a therapeutic agent
XX to treat bronchial asthma or chronic obstructive pulmonary disease; (3)
XX an animal model for bronchial asthma or chronic obstructive pulmonary
XX disease; (4) an inducer that induces bronchial asthma in a mouse; (5) a
XX method for producing an animal model for bronchial asthma or chronic
XX obstructive pulmonary disease; (6) a therapeutic agent for bronchial
XX asthma or chronic obstructive pulmonary disease, comprising a portion of
XX the marker gene or an antisense nucleic acid corresponding to a portion of
XX the marker gene; a ribozyme, a polynucleotide that suppresses the
XX expression of the gene through an RNAi effect or an antibody recognising
XX a protein encoded by a marker gene; and (7) a DNA chip for testing for
XX bronchial asthma or a chronic obstructive pulmonary disease, on which a
XX probe has been immobilised to assay a marker gene. (1) has respiratory
XX and antiasthmatic activities, and can be used in gene therapy. The method
XX is useful for testing for or screening for a therapeutic agent for
XX bronchial asthma or chronic obstructive pulmonary disease. The present

PF 13-NOV-2001; 2002US-0350666P.
XX 21-NOV-2001; 2001US-0332464P.
PR 29-NOV-2001; 2001US-0334393P.
PR 03-DEC-2001; 2001US-0335394P.
PR 14-DEC-2001; 2001US-0340376P.
PR 08-JAN-2002; 2002US-0347211P.
PR 10-JAN-2002; 2002US-0347349P.
PR 08-FEB-2002; 2002US-0355250P.
PR 13-FEB-2002; 2002US-0356714P.
PR 20-FEB-2002; 2002US-0359077P.
PR 29-MAR-2002; 2002US-0368809P.
PR 04-APR-2002; 2002US-0370110P.
PR 12-APR-2002; 2002US-0372246P.
PR 05-JUN-2002; 2002US-0386614P.
PR 16-JUL-2002; 2002US-0396839P.
PR 22-JUL-2002; 2002US-0397775P.
PR 22-JUL-2002; 2002US-0397845P.
PR 09-SEP-2002; 2002US-0409450P.
XX (EOSB-) EOS BIOTECHNOLOGY INC.
PA Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;
PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;
XX WPI; 2003-468649/44.
XX N-PSDB; ADN39271.
XX Determining the presence or absence of a pathological cell in a patient,
PT useful for diagnosing, prognosing or treating cancer, comprises detecting
PT a nucleic acid in a biological sample.
XX Claim 12; SEQ ID NO 590; 1385pp; English.
XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)
CC whose expression is upregulated or downregulated in specific cancers or
CC other diseases such as angiogenic or fibrotic disorders, and to methods
CC of determining the presence or absence of a pathological cell in a
CC patient by detecting a nucleic acid at least 80% identical to those of
CC the invention or by detecting a polypeptide of the invention. The
CC invention also relates to expression vectors and host cells comprising a
CC nucleic acid of the invention; antibodies which specifically bind a
CC polypeptide of the invention; use of such antibodies for drug targeting;
CC and methods of screening for modulators of activity or expression of the
CC polypeptides and nucleic acids. The nucleic acids, polypeptides,
CC antibodies and methods are useful for diagnosing, prognosing and treating
CC cancer and other conditions such as psoriasis, ischaemia, heart disease,
CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal
CC neovascularisation syndromes, scarring and uterine fibroids. They may
CC also be useful in wound healing and in contraception. The present
CC sequence represents a polypeptide of the invention.
XX SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 7; Length 766;
Best Local Similarity 100.0%; Pred. NO. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKTYTLTDYLNKTYRLKLSLRWISDHELYLKQENNLVFNAYGNSSVFLNSTFDEF 72
DB 39 SRKTYTLTDYLNKTYRLKLSLRWISDHELYLKQENNLVFNAYGNSSVFLNSTFDEF 98
QY 73 GHSINDYSISPDGQFILLENNYKQMRHSYASDYIDLKRLQILTEERIPNNQVWTWS 132
DB 99 GHSINDYSISPDGQFILLENNYKQMRHSYASDYIDLKRLQILTEERIPNNQVWTWS 158
QY 133 PVGHKLAYWNNDIYVKIEBNLPSYRITWTGKEDIYNGITDWMYEEVFSAYSAWSP 192
DB 159 PVGHKLAYWNNDIYVKIEBNLPSYRITWTGKEDIYNGITDWMYEEVFSAYSAWSP 218
QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRVPYKAGAVNPTVKFPVNTDLSLS 252

DB 219 NGTFLAYAQFNDTEVPLIEYSFYSDESLOYPKTVRVPYKAGAVNPTVKFPVNTDLSLS 278
QY 253 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIQNYSVMDICDYDESSGRWN 312
DB 279 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIQNYSVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTTGWGRFRPSPBPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 372
DB 339 CLVARQHIEMSTTGWGRFRPSPBPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 398
QY 373 KGTWEVIGIEALTSYLYIISNEYKGMFGGRNLYKIQLSYTKVTCLSCELNPERCQYYS 432
DB 399 KGTWEVIGIEALTSYLYIISNEYKGMFGGRNLYKIQLSYTKVTCLSCELNPERCQYYS 458
QY 433 VSPSKEAKYQLRCSGPGGLPLYTLHSSVNDKGLRVLEDSALDKMLQNVQMPSSKLDPII 492
DB 459 VSPSKEAKYQLRCSGPGGLPLYTLHSSVNDKGLRVLEDSALDKMLQNVQMPSSKLDPII 518
QY 493 LNETKFWYQMLPPHFDKSKYPLLLDVYAGCSOKADTVFRLNWTATYLASTENIIIVASF 552
DB 519 LNETKFWYQMLPPHFDKSKYPLLLDVYAGCSOKADTVFRLNWTATYLASTENIIIVASF 578
QY 553 DGRSGYQGDKIMHAINRRRLGTFEVEDQIEAARQFSKMGFVDNKRKRIAIWGSYGGYVTSM 612
DB 579 DGRSGYQGDKIMHAINRRRLGTFEVEDQIEAARQFSKMGFVDNKRKRIAIWGSYGGYVTSM 638
QY 613 VLGSYGKFCGIAVAPVSRWEYDVSYYTERYNGLPTPEDNLDHYRNSTVMSRAENPKQV 672
DB 639 VLGSYGKFCGIAVAPVSRWEYDVSYYTERYNGLPTPEDNLDHYRNSTVMSRAENPKQV 698
QY 673 EYLLIHGTADDNVHFQOQSAQISKALVDGVDFQAMWYTDSDHGIASSTAHOHYTHMSHP 732
DB 699 EYLLIHGTADDNVHFQOQSAQISKALVDGVDFQAMWYTDSDHGIASSTAHOHYTHMSHP 758
QY 733 IKQCFSLP 740
DB 759 IKQCFSLP 766
RESULT 8
ADJ83981
ID ADJ83981 standard; protein; 766 AA.
XX AC ADJ83981;
XX DT 06-MAY-2004 (first entry)
XX DE Human full-length colon dipeptidyl peptidase IV (DPP4V) protein.
XX KW crystal; proteni co-ordinate data; dipeptidyl peptidase IV; DPP4V;
KW immunomodulatory; antidiabetic; antiinflammatory; neuroprotective;
KW antithyroid; antirheumatic; antiarthritic; anti-Hiv; cytostatic;
KW immune response; diabetes; inflammation; multiple sclerosis;
KW Grave's disease; chronic rheumatoid arthritis; AIDS; cancer; human;
KW colon; enzyme.
XX OS Homo sapiens.
XX PN WO2004011640-A1.
XX PD 05-FEB-2004.
XX PF 28-JUL-2003; 2003WO-JP009523.
XX PR 29-JUL-2002; 2002US-0398761P.
XX PA (TANA) TANABE SEYAKU CO.
XX PI Hiramatsu H, Kyono K, Shima H, Sugiyama S;
XX WPI; 2004-156830/15.
XX DR N-PSDB; ADJ83980.
XX

DT 02-DEC-2004 (revised)
 DT 29-JAN-2004 (first entry)
 DE Human Protein AAA52308, SEQ ID NO 12620.
 XX Human; pain; neuronal tissue; gene therapy;
 KW spinal segmental nerve injury; chronic constriction injury; CCI;
 KW spared nerve injury; SNI; Chung.
 XX Homo sapiens.
 OS Unidentified.
 XX WO2003016475-A2.
 PN 27-FEB-2003.
 XX 14-AUG-2002; 2002WO-US025765.
 XX 14-AUG-2001; 2001US-0312147P.
 PR 01-NOV-2001; 2001US-0346382P.
 PR 26-NOV-2001; 2001US-0333347P.
 XX (GHEO) GEN HOSPITAL CORP.
 PA (FARB) BAYER AG.
 XX Woolf C, D'urzo D, Befort K, Costigan M;
 FI WPI; 2003-268312/26.
 XX GENBANK; AAA52308.
 DR New composition comprising two or more isolated polypeptides, useful for
 PT preparing a medicament for treating pain in an animal.
 XX Example 1; Page; 1017pp; English.
 XX The invention discloses a composition comprising two or more isolated rat
 CC or human polynucleotides or a polynucleotide which represents a fragment,
 CC derivative or allelic variation of the nucleic acid sequence. Also
 CC claimed are a vector comprising the novel polynucleotide, a host cell
 CC comprising the vector, a method for identifying a nucleotide sequence
 CC which is differentially regulated in an animal subjected to pain and a
 CC kit to perform the method, an array, a method for identifying an agent
 CC that increases or decreases the expression of the polynucleotide sequence
 CC that is differentially expressed in neuronal tissue of a first animal
 CC subjected to pain, a method for identifying a compound which regulates
 CC the expression of a polynucleotide sequence which is differentially
 CC expressed in an animal subjected to pain, a method for identifying a
 CC compound that regulates the activity of one or more of the
 CC polynucleotides, a method for producing a pharmaceutical composition, a
 CC method for identifying a compound or small molecule that regulates the
 CC activity in an animal of one or more of the polypeptides given in the
 CC specification, a method for identifying a compound useful in treating
 CC pain and a pharmaceutical composition comprising the one or more
 CC polypeptides or their antibodies. The polynucleotide or the compound that
 CC modulates its activity is useful for preparing a medicament for treating
 CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
 CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
 CC therapy). The sequence presented is a human protein (described in Table 3
 CC of the specification) which is differentially expressed during pain.
 CC Note: the sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic form directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 766 AA;
 SQ
 Query Match 98.0%; Score 3939; DB 7; Length 766;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 SRKTYLTDLKNTYRLKLYSLRWISDHELYLKQENNLVFNAYGNSVFLNSTFDEF 72
 DB 39 SRKTYLTDLKNTYRLKLYSLRWISDHELYLKQENNLVFNAYGNSVFLNSTFDEF 98

QY 73 GHSINDYSISPDGQFILLLENNYVQWRHSYTASVDIYDLNKRQLITEERIPIINTQWVTWS 132
 DB 99 GHSINDYSISPDGQFILLLENNYVQWRHSYTASVDIYDLNKRQLITEERIPIINTQWVTWS 158
 QY 133 PVGHKLAVVWNNDIYVKLEPNLPSYRITWTCKEDIYNGITDWVYEEBVSAYSALWSP 192
 DB 159 PVGHKLAVVWNNDIYVKLEPNLPSYRITWTCKEDIYNGITDWVYEEBVSAYSALWSP 218
 QY 193 NGTFLAVQAQFNDTEVPLIEYSFYSDLSLQYPKTVRVPYPKAGAVNPTVKFFVNTDSLS 252
 DB 219 NGTFLAVQAQFNDTEVPLIEYSFYSDLSLQYPKTVRVPYPKAGAVNPTVKFFVNTDSLS 278
 QY 253 VTNATSIQITAPASMLIGDHYLDCVWTWATQBRISLOWLRRIQNSVMDICDYDESSGRWN 312
 DB 279 VTNATSIQITAPASMLIGDHYLDCVWTWATQBRISLOWLRRIQNSVMDICDYDESSGRWN 338
 QY 313 CLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIIISNEGYRHCYFQIDKKDCTFIT 372
 DB 339 CLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIIISNEGYRHCYFQIDKKDCTFIT 398
 QY 373 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYVS 432
 DB 399 KGTWEVIGIEALTSDLYYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCELNPERCQYVS 458
 QY 433 VSFSEAKYQIQRCSGPGPLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSEKLDFTI 492
 DB 459 VSFSEAKYQIQRCSGPGPLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSEKLDFTI 518
 QY 493 LNETKFWYQMTILPHFDKSKYPLLLDYYAGPCSKADTVFRLNWTATYLASTENIIVASF 552
 DB 519 LNETKFWYQMTILPHFDKSKYPLLLDYYAGPCSKADTVFRLNWTATYLASTENIIVASF 578
 QY 553 DGRSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRRIALWGSYGGYVTSM 612
 DB 579 DGRSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRRIALWGSYGGYVTSM 638
 QY 613 VLGSYGKFGKGIAPVPSRWEYDVSVTERYMGUPTPEDNLDHYRNSTVMSRAENFKQV 672
 DB 639 VLGSYGKFGKGIAPVPSRWEYDVSVTERYMGUPTPEDNLDHYRNSTVMSRAENFKQV 698
 QY 673 EYLLHGTADDNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHOIYTHMSHF 732
 DB 699 EYLLHGTADDNVHVFQQAQISKALVDVGVDFQAMWYTDDEHGIASSTAHOIYTHMSHF 758
 QY 733 IKQCFSLP 740
 DB 759 IKQCFSLP 766
 RESULT 7
 ADN39272
 ID ADN39272 standard; protein; 766 AA.
 XX AC ADN39272;
 XX DT 17-JUN-2004 (first entry)
 XX DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:590.
 XX KW Human; differential expression; cancer; angiogenic disorder;
 KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;
 KW inflammatory disease; autoimmune disease;
 KW retinal neovascularisation syndrome; scarring; uterine fibroid;
 KW detection; diagnosis; prognosis; drug screening; drug targeting;
 KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;
 KW vulnerrary; gene therapy; vaccine.
 XX OS Homo sapiens.
 XX PN WO2003042661-A2.
 XX PD 22-MAY-2003.
 XX XX


```
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 SRKTYTLTDYLNKNTYRLKLSLRWISDHEYLKQENNILVFNABYGNSSVPLENSTFDF 72
Db 39 SRKTYTLTDYLNKNTYRLKLSLRWISDHEYLKQENNILVFNABYGNSSVPLENSTFDF 98
QY 73 GHSINDYSIPDGPQFILLEYNVVKQWRHSYTSYDIYDLNKRQLITEERIPNNTQVWTWS 132
Db 99 GHSINDYSIPDGPQFILLEYNVVKQWRHSYTSYDIYDLNKRQLITEERIPNNTQVWTWS 158
QY 133 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSLWWS 192
Db 159 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSLWWS 218
QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYKPTVRVPYPKAGAVNPTVKFFVNTDLS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYKPTVRVPYPKAGAVNPTVKFFVNTDLS 278
QY 253 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICVFQIDKDCCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICVFQIDKDCCTFIT 398
QY 373 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSDYTKVCLSCELNPERCQYYS 432
Db 399 KGTWEVIGIEALTSYLYISNEYKMGPGGRNLYKIQLSDYTKVCLSCELNPERCQYYS 458
QY 433 VSFSEAKYQLRCSGPGPLPYTLHSSVNDKGLRVLEDSALDKMLQNVQWPSKKLDPII 492
Db 459 VSFSEAKYQLRCSGPGPLPYTLHSSVNDKGLRVLEDSALDKMLQNVQWPSKKLDPII 518
QY 493 LNETKFWQMTILPPHFDKSKYPLLLDVTYVAGPCOKADTVPRLNWATYLASTENIIVASF 552
Db 519 LNETKFWQMTILPPHFDKSKYPLLLDVTYVAGPCOKADTVPRLNWATYLASTENIIVASF 578
QY 553 DGRSGYQGDKIMHAINRRLGTFFVEDQIEARQFSKMGFVNDKRIAGWSYGGYVTSM 612
Db 579 DGRSGYQGDKIMHAINRRLGTFFVEDQIEARQFSKMGFVNDKRIAGWSYGGYVTSM 638
QY 613 VLGSYGVPKCGIAVAPVSRWEYDYSVYTERVWGLPTPEDNLDHYRNSTWMSRAENFKQV 672
Db 639 VLGSYGVPKCGIAVAPVSRWEYDYSVYTERVWGLPTPEDNLDHYRNSTWMSRAENFKQV 698
QY 673 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTTDEDHGIASSTAHOHIYTHMSHF 732
Db 699 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTTDEDHGIASSTAHOHIYTHMSHF 758
QY 733 IKQCFSLP 740
Db 759 IKQCFSLP 766
RESULT 4
AAG78417
XX ID AAG78417 standard; protein; 766 AA.
XX AC AAG78417;
XX DT 12-APR-2002 (first entry)
XX DE Human dipeptidyl peptidase IV amino acid sequence.
XX KW 21953 prolyl oligopeptidase; antibody; proline; endopeptidase; cancer;
KW cardiovascular disease; autoimmune disease; atopic allergy;
KW neuronal disorder; vascular disorder; prostate disorder; cytostatic;
KW antidiabetic; antiarthritic; antiasthmatic; antiinflammatory;
KW diabetes mellitus; arthritis; multiple sclerosis; asthma;
KW Grave's disease; neuronal disorder; demyelinating disease;
KW dipeptidyl peptidase.
XX
```

```
OS Homo sapiens.
XX WO200179473-A2.
XX 25-OCT-2001.
XX 11-APR-2001; 2001WO-US040483.
XX 18-APR-2000; 2000US-0197508P.
XX (MILL-) MILLENNIUM PHARM INC.
XX Meyers RA, Williamson M;
XX WPI; 2002-034353/04.
XX New polypeptides 21953, member of human prolyl oligopeptidase family,
XX useful as diagnostic targets and therapeutic agents for controlling
XX cancer, lymphoma and leukemia.
XX Disclosure; Fig 3; 121pp; English.
XX This invention relates to an isolated 21953 human prolyl oligopeptidase.
XX Which is cytostatic, antidiabetic, antiarthritic, neuroprotective,
XX antithyroid, dermatological, antipsoriatic, antiasthmatic,
XX ophthalmological, antiinflammatory, nootropic, antiparkinsonian,
XX anticonvulsant, gynaecological, vasotropic, antianginal, cardiac,
XX antiatherosclerotic, anorectic and metabolic in its action. Uses include
XX gene therapy, expression or activity of 21953 protein modulator, it is
XX useful for identifying a compound which binds to it and can be used in
XX preventing, treating or detecting a cellular proliferative or
XX differentiative disorder. The 21953 molecules can act as novel diagnostic
XX targets and therapeutic agents for controlling disorders associated with
XX the aberrant activity or degradation of peptide hormones e.g., disorders
XX associated with cell differentiation and proliferation such as cancer,
XX immune function, reproductive, neurological and cardiovascular function.
XX The 21953 molecules are thus useful for treating and preventing cellular
XX proliferative and differentiative disorders, haematopoietic neoplastic
XX disorders, immune disorders such as autoimmune diseases, diabetes
XX mellitus, arthritis, multiple sclerosis, asthma, Grave's disease,
XX neuronal disorders, demyelinating diseases, vascular disorders and
XX metabolism or pain disorders. This sequence represents the amino acid
XX sequence of human dipeptidyl peptidase IV
XX Sequence 766 AA;
```

```
Query Match 98.0%; Score 3939; DB 5; Length 766;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 13 SRKTYTLTDYLNKNTYRLKLSLRWISDHEYLKQENNILVFNABYGNSSVPLENSTFDF 72
Db 39 SRKTYTLTDYLNKNTYRLKLSLRWISDHEYLKQENNILVFNABYGNSSVPLENSTFDF 98
QY 73 GHSINDYSIPDGPQFILLEYNVVKQWRHSYTSYDIYDLNKRQLITEERIPNNTQVWTWS 132
Db 99 GHSINDYSIPDGPQFILLEYNVVKQWRHSYTSYDIYDLNKRQLITEERIPNNTQVWTWS 158
QY 133 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSLWWS 192
Db 159 PVGHKLAVVWNNDIYVKIEPNLPSYRIITWTGKEDIYNGITDWTVEEVEFSAYSLWWS 218
QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYKPTVRVPYPKAGAVNPTVKFFVNTDLS 252
Db 219 NGTFLAYAQFNDTEVPLIEYSFYSDLSQYKPTVRVPYPKAGAVNPTVKFFVNTDLS 278
QY 253 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 312
Db 279 VTNATSIQITAPASMLIGDHYLCDVTWATQERISLOWLRRIONYSVMDICDYDESSGRWN 338
QY 313 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICVFQIDKDCCTFIT 372
Db 339 CLVARQHIEMSTTGWGRFRPSEPHFTLDGNSFYKIIISNEEGYRHICVFQIDKDCCTFIT 398
```

FT Region 552..766
 FT /label= C-terminal region of extracellular domain
 FT /note= "1 N-linked glycosylation site & 1 catalytic site"
 FT Active-site 627..631
 FT /label= active site of serine protease/esterase
 FT /note= "fits the consensus sequence GXSG"
 FN W09316102-A1.
 XX
 XX
 XX 19-AUG-1993.
 XX
 PF 09-APR-1992; 92WO-US002892.
 XX
 PR 06-FEB-1992; 92US-00832211.
 XX
 XX (DAND) DANA FARBER CANCER INST INC.
 XX
 FI Morimoto C, Schloeman SP, Tanaka T;
 XX
 DR WPI; 1993-272827/34.
 DR N-PSDB; AAQ46089.
 XX
 PT Polypeptide fragments of CD26 - are capable of disrupting binding of CD45
 PT and CD26 and thus interfering with T-cell activation.
 XX
 PS Disclosure; Page 39-43; 73pp; English.
 XX
 CC C26 is a human T cell activation antigen originally identified by its
 CC reactivity with the MAB Tal. C26 cDNA library was constructed from human
 CC PHA-activated T cells using the CMV/vector. The hydrophobic N-terminal of
 CC the predicted C26 polypeptide has the characteristics of a signal
 CC sequence of the type II membrane protein, which is reinforced by the
 CC observation that potential N-glycosylation sites are located in the
 CC carboxy side of the hydrophobic core. Therefore the N-terminal 6 AAs are
 CC predicted to be cytoplasmic, the next 22 AAs are predicted to transverse
 CC the cytoplasmic membrane, and the 738 C-terminal AAs constitute the
 CC predicted extracellular domain. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 2; Length 766;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKTYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFNABYGNSSVFLNSTDFEF 72
 DB 39 SRKTYTLTDYLNKTYRLKLYSLRWISDHEYLKQENNILVFNABYGNSSVFLNSTDFEF 98
 QY 73 GHSINDYSISPDGQFILLVYVQWRHSYASDYDVLNKRQLITEERIPNNTQWTVWS 132
 DB 99 GHSINDYSISPDGQFILLVYVQWRHSYASDYDVLNKRQLITEERIPNNTQWTVWS 158
 QY 133 PVGHKLAYVWNNDIYVVKIEPNLPSYRITWTGKEDIYNGITDWWYEEVFSAYGALWSP 192
 DB 159 PVGHKLAYVWNNDIYVVKIEPNLPSYRITWTGKEDIYNGITDWWYEEVFSAYGALWSP 218
 QY 193 NGTFLAYAFQNDTEVPLIEISFYDESLOYPKTVVPYKAGAVNPTKFPVNTDSLSS 252
 DB 219 NGTFLAYAFQNDTEVPLIEISFYDESLOYPKTVVPYKAGAVNPTKFPVNTDSLSS 278
 QY 253 VTNATSIQITAPASMLGDHYLDCVWTATQERISLOWLRRIONYSVMDICDYDESSGRWN 312
 DB 279 VTNATSIQITAPASMLGDHYLDCVWTATQERISLOWLRRIONYSVMDICDYDESSGRWN 338
 QY 313 CLVARQHIEMSTTGWGRPRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 372
 DB 339 CLVARQHIEMSTTGWGRPRPSEPHFTLDGNSFYKIIISNEEGYRHCYFQIDKKDCTFIT 398
 QY 373 KGTWEVIGIEALTSDYLYISNEYKMGPGGRNLYKIQLSDYTKVTCISCELNPERCOYYS 432
 DB 399 KGTWEVIGIEALTSDYLYISNEYKMGPGGRNLYKIQLSDYTKVTCISCELNPERCOYYS 458

QY 433 VFSKEARYQLRCGPGCLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDPII 492
 DB 459 VFSKEARYQLRCGPGCLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDPII 518
 QY 493 LNETKFWYQMLPPHFDKSKKYPILLDYVYAGPCSKQADTVPRLNWATYLASTENIIVASF 552
 DB 519 LNETKFWYQMLPPHFDKSKKYPILLDYVYAGPCSKQADTVPRLNWATYLASTENIIVASF 578
 QY 553 DGRSGYQGDKIMHAINRRLTGTFEVDQIEAAROFKMGFVDNKRKRIATWGSYGGYVTSM 612
 DB 579 DGRSGYQGDKIMHAINRRLTGTFEVDQIEAAROFKMGFVDNKRKRIATWGSYGGYVTSM 638
 QY 613 VLGSQGVFKGCIAPVPSRWEYDVSVYTERYMGCLPTPEDNLDHYRNSTVMSRAENFKQV 672
 DB 639 VLGSQGVFKGCIAPVPSRWEYDVSVYTERYMGCLPTPEDNLDHYRNSTVMSRAENFKQV 698
 QY 673 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIYTHMSHF 732
 DB 699 EYLLIHGTADDNVHFQOQAISKALVDVGVDFQAMWYTDDEHGIASSTAHQHIYTHMSHF 758
 QY 733 IKQCFSLP 740
 DB 759 IKQCFSLP 766

RESULT 3
 ABB08991
 ID ABB08991 standard; protein; 766 AA.
 AC ABB08991;
 XX
 DT 19-JUN-2002 (first entry)
 XX
 DE Human dipeptidyl peptidase IV.
 XX
 KW Human; dipeptidyl peptidase IV; antiasthmatic; antiallergic;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 FN US6337069-B1.
 XX
 PD 08-JAN-2002.
 XX
 PF 28-FEB-2001; 2001US-00794236.
 XX
 PR 28-FEB-2001; 2001US-00794236.
 XX
 PA (BMRA-) BMRA CORP BV.
 XX
 PI Grouzmann E, Lacroix J, Monod M;
 XX
 DR WPI; 2002-163235/21.
 XX
 PT Treating a patient for mucosal inflammation associated with rhinitis,
 PT sinusitis or both, by intranasally administering a peptidase that cleaves
 PT at Xaa-Pro sequences, to the patient.
 XX
 PS Disclosure; Col 9-14; 13pp; English.
 XX
 CC Thus invention relates to the treating of a patient for mucosal
 CC inflammation associated with rhinitis or sinusitis, comprising
 CC intranasally administering a peptidase. The peptidase is considered
 CC antiasthmatic, antiallergic and antiinflammatory in its action. The
 CC peptidase cleaves at Xaa-Pro sequences and is useful for treating a
 CC patient for mucosal inflammation associated with rhinitis or sinusitis,
 CC which is the result of allergies or asthma. This sequence represents
 CC human dipeptidyl peptidase IV
 XX
 SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 5; Length 766;
 Best Local Similarity 100.0%; Pred. No. 0;

98 1002 24.9 988 4 ABB65641 AbB65641 Drosophil
99 998 24.8 775 9 ADY51819 AdY51819 T. rubrum
100 987 24.6 771 2 AAW89589 Aaw89589 Aspergill

ALIGNMENTS

RESULT 1

ID AAR54612 standard; protein; 759 AA.

XX AC AAR54612;

DT 25-MAR-2003 (revised)
DT 09-DEC-1994 (first entry)

XX DE Delta3-9 CD26.

XX KW Human; T cell activation antigen; CD26; analogues; deletion; soluble;
KW signal peptidase; immune-stimulating; response-stimulating; AIDS;
KW immunosuppression; AIDS-related complex.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Misc-difference 2..3 /note= "Position of delta3-9 deletion"

XX PN WO9409132-A1.

XX PD 28-APR-1994.

XX PF 19-AUG-1993; 93WO-US007923.

XX PR 21-AUG-1992; 92US-00934162.

XX PA (DAND) DANA FARBER CANCER INST INC.

XX PI Morimoto C, Schlozman S, Tanaka T;

XX DR WPI; 1994-151317/18.

XX PT Polypeptide fragments and analogues of CD26 and encoding nucleic acid -
PT useful for stimulating immune response, e.g. for treatment of AIDS to
PT counteract immunosuppressive drug, and as vaccine adjuvant.

XX PS Claim 3; Page 49-52; 85pp; English.

CC The sequences given in AAR54612-14 represents analogues of the human T
CC cell activation antigen CD26 which have internal deletions. The analogues
CC pref. lack residues 3-9 or 24-34. These analogues are soluble under
CC physiological conditions and lack enough amino acid residues to render
CC them susceptible to cleavage by signal peptidase. The peptide fragments
CC and analogues are useful as immune or response-stimulating therapeutics,
CC eg. they may be used for treatment of disease conditions characterised by
CC immunosuppression, eg. AIDS or AIDS-related complex, other virally or
CC environmentally-induced conditions, and certain congenital immune
CC deficiencies. The peptides can be employed to increase immune function
CC which has been impaired by use of immunosuppressive drugs, such as certain
CC chemotherapeutic drugs. (Updated on 25-MAR-2003 to correct PN field.)

SQ Sequence 759 AA;

Query Match 98.0%; Score 3939; DB 2; Length 759;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 SRKTYTLDTYLRKLYSLRWISDHEYLKQENNLVFNAYGNSVFLNSTFDEF 72

DB 32 SRKTYTLDTYLRKLYSLRWISDHEYLKQENNLVFNAYGNSVFLNSTFDEF 91

QY 73 GHSINDYSISPDQGFILLEYNYVKWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWS 132

Db 92 GHSINDYSISPDQGFILLEYNYVKWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWS 151
QY 133 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKBDIIYNGITDWDVVEEVSAYGALWWSF 192
Db 152 PVGHKLAVVWNNDIYVKIEPNLPSYRITWTGKBDIIYNGITDWDVVEEVSAYGALWWSF 211
QY 193 NGTFLAYAQFNDTEVPLIEYSFYSDSLQYPKTVRVPYKAGAVNPTVKFFVAVNTDSLSS 252
Db 212 NGTFLAYAQFNDTEVPLIEYSFYSDSLQYPKTVRVPYKAGAVNPTVKFFVAVNTDSLSS 271
QY 253 VTNATSIQITAPASMLIGDHYLCDVTWATQBRISLOMLRRIQNTSVMDICDYDESSGRWN 312
Db 272 VTNATSIQITAPASMLIGDHYLCDVTWATQBRISLOMLRRIQNTSVMDICDYDESSGRWN 331
QY 313 CLVARQHIEMSTTCWVGFRPSPBPHFTLDGNSFYKIIISNEGYRHHICVFQIDKKDCTFIT 372
Db 332 CLVARQHIEMSTTCWVGFRPSPBPHFTLDGNSFYKIIISNEGYRHHICVFQIDKKDCTFIT 391
QY 373 KGTWEVIGIEALTSDYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCENLPERCQYYS 432
Db 392 KGTWEVIGIEALTSDYLYIISNEYKMGPGGRNLYKIQLSDYTKVTCLSCENLPERCQYYS 451
QY 433 VSPSKEAKYIQLRCGSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQWPSKCLDFII 492
Db 452 VSPSKEAKYIQLRCGSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQWPSKCLDFII 511
QY 493 LNETKFWYQMLTPPHFDKSKYPLLDDVYAGPCSKADTVFRLNWTATLASTENIIVASF 552
Db 512 LNETKFWYQMLTPPHFDKSKYPLLDDVYAGPCSKADTVFRLNWTATLASTENIIVASF 571
QY 553 DGRSGYQGDKIMHAINRRRLGTPEVEDQIEAARQFSKMGFVDNKRKIAIIGWWSYGYVTSM 612
Db 572 DGRSGYQGDKIMHAINRRRLGTPEVEDQIEAARQFSKMGFVDNKRKIAIIGWWSYGYVTSM 631
QY 613 VLGSQGVFKCGIAVAPVSRWEYDVSUTERYNGLPTPEDNLDHYRNSTVMSRAENFKQV 672
Db 632 VLGSQGVFKCGIAVAPVSRWEYDVSUTERYNGLPTPEDNLDHYRNSTVMSRAENFKQV 691
QY 673 EYLLIHGTADDNVHVFQSSAQISKALVDVGVDFQAWWYTDDEHGIASSTAHOHIYTHMSHF 732
Db 692 EYLLIHGTADDNVHVFQSSAQISKALVDVGVDFQAWWYTDDEHGIASSTAHOHIYTHMSHF 751
QY 733 IKQCFSLP 740
Db 752 IKQCFSLP 759

RESULT 2

AAR40909

ID AAR40909 standard; protein; 766 AA.

XX AC AAR40909;

XX DT 25-MAR-2003 (revised)

DT 05-FEB-1994 (first entry)

XX DE Sequence encoded by human CD26 cDNA.

XX KW Human T cell activation antigen; monoclonal antibody Tal.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Region 7..28 /label= hydrophobic

FT Region 29..323 /label= N-terminal glycosylated region of extracellular

FT domain /note= "8 sites for N-linked glycans"

FT Region 324..551 /label= Cysteine rich region of extracellular domain

FT /note= "1 N-linked glycosylation site"

